var title_f0_43_688="CBD transection MRCP";
var content_f0_43_688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete common bile duct transection after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRCP showing absence of the common bile duct and dilated intrahepatic ducts in a patient with complete transection of the common bile duct. A pool of fluid is seen at the confluence of the right and left hepatic ducts (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_688=[""].join("\n");
var outline_f0_43_688=null;
var title_f0_43_689="Axial CT six months";
var content_f0_43_689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial CT six months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 77-year-old woman with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk factors. Contrast-enhanced axial CT at six-months. The area treated has decreased in size without evidence of enhancement (arrow), findings consistent with successful tumor ablation. A small calcified granuloma is present anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Schirmang, T, MD and Dupuy, D, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_689=[""].join("\n");
var outline_f0_43_689=null;
var title_f0_43_690="Erythema multiforme elbow";
var content_f0_43_690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child with erythema multiforme has multiple erythematous plaques and some vesicles on the elbows. A few true target lesions are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_690=[""].join("\n");
var outline_f0_43_690=null;
var title_f0_43_691="Nedocromil: Drug information";
var content_f0_43_691=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nedocromil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/41/7828?source=see_link\">",
"    see \"Nedocromil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23122?source=see_link\">",
"    see \"Nedocromil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alocril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alocril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Mast Cell Stabilizer",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: 1-2 drops in each eye twice daily throughout the period of exposure to allergen",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23122?source=see_link\">",
"      see \"Nedocromil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Children &ge;3 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alocril&reg;: 2% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5283261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only; do not allow tip of container to touch eye, surrounding structures, fingers, or other surfaces to avoid bacterial contamination.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of itching associated with allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Unpleasant taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Burning, irritation, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, eye redness, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nedocromil or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic solution: Contains benzalkonium chloride, which may be absorbed by contact lenses; users of contact lenses should not wear them during periods of symptomatic allergic conjunctivitis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5282499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity or harm to fetus. Additionally, nedocromil has minimal systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F200215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alocril Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (5 mL): $142.54",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Brionil (ES);",
"     </li>",
"     <li>",
"      Cetimil (ES);",
"     </li>",
"     <li>",
"      Halamid (DE);",
"     </li>",
"     <li>",
"      Ildor (ES);",
"     </li>",
"     <li>",
"      Irtan (DE, MX);",
"     </li>",
"     <li>",
"      Kovilen (IT);",
"     </li>",
"     <li>",
"      Kovinal (IT);",
"     </li>",
"     <li>",
"      Nedocromil-Natrium &rdquo;Schoeller Pharma&rdquo; (AT);",
"     </li>",
"     <li>",
"      Telavist (FR);",
"     </li>",
"     <li>",
"      Tilad (ES);",
"     </li>",
"     <li>",
"      Tilade (AR, AT, BR, CZ, DE, DK, ES, FI, GB, GR, HU, ID, IE, IT, LU, NL, PL);",
"     </li>",
"     <li>",
"      Tilade CFC Free (AU);",
"     </li>",
"     <li>",
"      Tilade Mint (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tilarin (AT, FI, IT, PL);",
"     </li>",
"     <li>",
"      Tilavist (AT, CH, DK, ES, IL, IT, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the activation of and mediator release from a variety of inflammatory cell types associated with hypersensitivity reactions including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets; it inhibits the release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Low (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine 70% (as unchanged drug); feces 30% (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9987 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_691=[""].join("\n");
var outline_f0_43_691=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200225\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200226\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200259\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200228\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200243\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200229\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200207\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200196\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5283261\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200210\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200257\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200213\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200199\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299748\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200204\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5282499\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200231\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200215\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200216\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200198\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200212\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/41/7828?source=related_link\">",
"      Nedocromil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23122?source=related_link\">",
"      Nedocromil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_43_692="Patient information: Type 1 diabetes (The Basics)";
var content_f0_43_692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/52/37699\">",
"         Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/26/39331\">",
"         Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36483\">",
"         Patient information: Diabetes and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/52/20292\">",
"         Patient information: Diabetes and infections (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/34/11810\">",
"         Patient information: Diabetic retinopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/33/5651\">",
"         Patient information: Giving your child insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/14/227\">",
"         Patient information: Hemoglobin A1C tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/25/36243\">",
"         Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/12/14531\">",
"         Patient information: Low blood sugar in people with diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/11/38066\">",
"         Patient information: Managing diabetes in school (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/48/18179\">",
"         Patient information: My child has diabetes: How will we manage? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/47/20208\">",
"         Patient information: Nerve damage caused by diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/47/6899\">",
"         Patient information: Should I switch to an insulin pump? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/40/22144\">",
"         Patient information: The ABCs of diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/58/28579\">",
"         Patient information: Using insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/31/35317\">",
"         Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/26/36259\">",
"         Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/4/24644\">",
"         Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/63/4083\">",
"         Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/20/3397\">",
"         Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Type 1 diabetes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/type-1-diabetes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31795486\">",
"      <span class=\"h1\">",
"       What is type 1 diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Type 1 diabetes (sometimes called type 1 &ldquo;diabetes mellitus&rdquo;) is a disorder that disrupts the way your body uses sugar.",
"     </p>",
"     <p>",
"      All the cells in your body need sugar to work normally. Sugar gets into cells with the help of a hormone called insulin. If there is not enough insulin, or if the body stops responding to insulin, sugar builds up in the blood. That is what happens to people with diabetes.",
"     </p>",
"     <p>",
"      There are two types of diabetes. People with type 1 diabetes make little or no insulin. People with type 2 diabetes sometimes also make too little insulin, but more often the problem is that their cells do not respond to insulin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795493\">",
"      <span class=\"h1\">",
"       What are the symptoms of type 1 diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Intense thirst",
"       </li>",
"       <li>",
"        Being very tired",
"       </li>",
"       <li>",
"        Urinating often",
"       </li>",
"       <li>",
"        Losing weight",
"       </li>",
"       <li>",
"        Blurred vision",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In extreme cases, type 1 diabetes can also cause nausea or vomiting, belly pain, and panting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795500\">",
"      <span class=\"h1\">",
"       How do I know if I have type 1 diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse can do a blood test to measure the amount of sugar in your blood. The test will show whether you have diabetes. If you do, your doctor or nurse can then decide whether it is type 1 or type 2&mdash;based on your age, your weight, and other factors.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795507\">",
"      <span class=\"h1\">",
"       How is type 1 diabetes treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for type 1 diabetes involves two key parts:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Measuring your blood sugar often, to make sure it does not get too high or too low. (Your doctor or nurse will explain how to measure your blood sugar, and how often to do it.)",
"       </li>",
"       <li>",
"        Using insulin shots or an insulin pump to keep your blood sugar levels in the right range. (An insulin pump is a device that you wear close to your body. It is connected to tube that goes under your skin and supplies insulin.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with type 1 diabetes also need to carefully plan their meals and activity levels. That's because eating raises blood sugar, while being active lowers it. Despite the need to plan, people with diabetes can have normal diets, be active, eat out, and do all the things that most other people do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795514\">",
"      <span class=\"h1\">",
"       How often do I need to see my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will probably need to see your doctor or nurse at least 3 or 4 times a year. Sometimes you will need more visits to learn how to manage your diabetes or if your blood sugar is not well controlled.",
"     </p>",
"     <p>",
"      During your visits, your doctor or nurse will want to measure your blood sugar using a test called &ldquo;A1c.&rdquo; This test tells you your average blood sugar level over the last few months. Its results will help your doctor or nurse decide whether to adjust your treatment.",
"     </p>",
"     <p>",
"      During some of your visits, your doctor or nurse will also check other aspects of your health. For instance, he or she might measure your blood pressure or cholesterol. It is very important that you keep all your appointments with your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795521\">",
"      <span class=\"h1\">",
"       Why is it important to keep my blood sugar close to normal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having high blood sugar can cause serious problems over time. It can lead to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nerve damage",
"       </li>",
"       <li>",
"        Kidney disease",
"       </li>",
"       <li>",
"        Vision problems (or even blindness)",
"       </li>",
"       <li>",
"        Pain or loss of feeling in the hands and feet",
"       </li>",
"       <li>",
"        The need to have fingers, toes, or other body parts removed (amputated)",
"       </li>",
"       <li>",
"        Heart disease and strokes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Having",
"      <strong>",
"       low",
"      </strong>",
"      blood sugar can cause problems, too. It can make your heart beat fast, and make you shake and sweat. If blood sugar gets really low, it can cause more serious problems, too. People with very low blood sugar can get headaches, get very sleepy, pass out, or even have seizures.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795528\">",
"      <span class=\"h1\">",
"       Why is it important to keep my blood pressure and cholesterol low?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with diabetes have a much higher risk of heart disease and strokes than people who do not have diabetes. Keeping blood pressure and cholesterol low can help lower those risks.",
"     </p>",
"     <p>",
"      If your doctor or nurse puts you on blood pressure or cholesterol medicines, be sure to take them. Studies show that these medicines can prevent heart attacks, strokes, and even death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795535\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women with type 1 diabetes have healthy pregnancies. If you want to have a baby, make sure you control your blood sugar really well before and during pregnancy. This will protect you and your baby from problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31795542\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"       Patient information: Diabetes and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=see_link\">",
"       Patient information: Hemoglobin A1C tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"       Patient information: The ABCs of diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=see_link\">",
"       Patient information: Diabetic retinopathy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"       Patient information: Nerve damage caused by diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"       Patient information: Low blood sugar in people with diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       Patient information: Using insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"       Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=see_link\">",
"       Patient information: My child has diabetes: How will we manage? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=see_link\">",
"       Patient information: Managing diabetes in school (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=see_link\">",
"       Patient information: Giving your child insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=see_link\">",
"       Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=see_link\">",
"       Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/52/20292?source=see_link\">",
"       Patient information: Diabetes and infections (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"       Patient information: Should I switch to an insulin pump? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"       Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/20/3397?source=see_link\">",
"       Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24644?source=see_link\">",
"       Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/43/692?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15401 Version 7.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9B173040F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_692=[""].join("\n");
var outline_f0_43_692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795486\">",
"      What is type 1 diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795493\">",
"      What are the symptoms of type 1 diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795500\">",
"      How do I know if I have type 1 diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795507\">",
"      How is type 1 diabetes treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795514\">",
"      How often do I need to see my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795521\">",
"      Why is it important to keep my blood sugar close to normal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795528\">",
"      Why is it important to keep my blood pressure and cholesterol low?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795535\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31795542\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/52/20292?source=related_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24644?source=related_link\">",
"      Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=related_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=related_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=related_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=related_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/20/3397?source=related_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_43_693="Dienogest: Patient drug information";
var content_f0_43_693=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dienogest: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27366?source=see_link\">",
"     see \"Dienogest: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13450885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Visanne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13452138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pain caused by endometriosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13452099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dienogest or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, diseased arteries in the brain, eyesight loss, recent heart attack, disease of a heart valve with problems, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13452101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13452319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13452102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13452139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2762619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 2 hours of taking this drug, take 1 more dose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13452100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13452320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13452103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17069 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_693=[""].join("\n");
var outline_f0_43_693=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450885\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452138\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452099\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452101\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452319\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452102\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452139\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452100\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452320\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452103\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27366?source=related_link\">",
"      Dienogest: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_43_694="Allergic contact dermatitis face";
var content_f0_43_694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intense inflammatory eruption is present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_694=[""].join("\n");
var outline_f0_43_694=null;
var title_f0_43_695="Hemangioblastoma";
var content_f0_43_695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemangioblastoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/695/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/695/contributors\">",
"     Eric T Wong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/695/contributors\">",
"     Jeffrey Joseph, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/695/contributors\">",
"     Julian K Wu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/695/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/695/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/695/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/695/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/43/695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas are uncommon, slow-growing tumors of the central nervous system, which most commonly occur in the cerebellum, brainstem, or spinal cord. They account for approximately 4 percent of all spinal cord tumors, and 7 to 10 percent of tumors arising in the posterior fossa in adults.",
"   </p>",
"   <p>",
"    Hemangioblastomas occur both sporadically and as an important component of von Hippel-Lindau (VHL) disease, along with retinal angiomas, renal cell carcinoma, pheochromocytomas, pancreatic cysts and neuroendocrine tumors.",
"   </p>",
"   <p>",
"    The clinical manifestations and management of patients with hemangioblastomas are reviewed here. The clinical manifestations and overall management of patients with VHL disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sporadic versus VHL-associated tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas may occur either sporadically or as a manifestation of VHL disease. Although approximately 75 percent of all hemangioblastomas appear to be sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/1\">",
"     1",
"    </a>",
"    ], some of these may represent occult cases of VHL that can be detected if patients are appropriately screened for germline VHL mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Hemangioblastomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic and VHL-related hemangioblastomas differ significantly in their presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic hemangioblastomas are usually solitary. Thus, the presence of multiple tumors within the neuraxis should raise suspicion for VHL disease.",
"     </li>",
"     <li>",
"      Hemangioblastomas associated with VHL are generally diagnosed at a younger age than sporadic tumors. In one series, the mean age at initial diagnosis was 29 years in patients with VHL, while the average age at presentation in those without VHL is one to two decades older [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with VHL disease, approximately one-half of tumors are in the spinal cord, 40 percent are in the cerebellum, and 10 percent are in the brainstem [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/2\">",
"       2",
"      </a>",
"      ]. Supratentorial lesions are rare. For those with sporadic tumors, isolated cerebellar lesions are substantially more common [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of more than one hemangioblastoma, an early age at diagnosis, or the presence of other manifestations of VHL disease should all serve as an indication for genetic screening for germline VHL mutations (",
"    <a class=\"graphic graphic_table graphicRef66320 \" href=\"UTD.htm?12/45/13020\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas can cause local symptoms by compression of neural structures, bleeding, or paraneoplastic complications. In patients with VHL disease, asymptomatic hemangioblastomas are diagnosed based upon imaging surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Surveillance protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemangioblastomas can cause neurologic deficits by direct compression or tumor-associated hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The specific deficit from direct compression depends upon tumor location, and may include cerebellar ataxia, oculomotor nerve dysfunction, motor weakness, or sensory deficits. Patients with spinal hemangioblastomas frequently present with pain [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute hemorrhage can be catastrophic. Intracerebral bleeding from a cerebellar hemangioblastoma may cause rapid obstructive hydrocephalus, cerebellar tonsillar herniation, or brainstem compression [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Bleeding from a spinal hemangioblastoma may result in acute quadriplegia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/6\">",
"       6",
"      </a>",
"      ], while headache, back pain, or radiculopathy may be caused by subarachnoid hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In these situations, emergency neurosurgical intervention is indicated. The risk of bleeding in treated or untreated hemangioblastomas is unknown. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paraneoplastic erythrocytosis has also been reported in patients with hemangioblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The elevated hematocrit and red cell mass are a result of excessive erythropoietin production by the hemangioblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link\">",
"     \"Diagnostic approach to the patient with polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred diagnostic procedure is gadolinium-enhanced magnetic resonance imaging (MRI). A CT scan of the neuraxis is not an adequate diagnostic procedure because bone artifacts may obscure small tumors in the posterior fossa or spinal canal. For patients who cannot undergo an MRI, conventional angiography together with CT scanning are alternative diagnostic tests to define the location and vasculature feeding the hemangioblastoma.",
"   </p>",
"   <p>",
"    The characteristic MRI feature of hemangioblastomas is an enhancing nodule associated with a cyst located in the cerebellum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63358 \" href=\"UTD.htm?40/11/41136\">",
"     image 1",
"    </a>",
"    ) or a homogeneously enhancing lesion on the surface of or within the spinal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79982 \" href=\"UTD.htm?35/57/36754\">",
"     image 2",
"    </a>",
"    ). These features are not pathognomonic, and the differential diagnosis includes astrocytoma, ganglioglioma, or metastatic tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=see_link\">",
"     \"Diagnosis and classification of low-grade gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"     \"Spinal cord tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smaller hemangioblastomas (&lt;10 mm) may be isointense on T1-weighted images and hyperintense on T2-weighted images, with homogeneous contrast enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/13\">",
"     13",
"    </a>",
"    ]. Spinal hemangioblastomas are often associated with a syrinx or spinal cord edema [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas are well-circumscribed, highly vascular red nodules that are often located within the walls of large cysts (",
"    <a class=\"graphic graphic_picture graphicRef60110 \" href=\"UTD.htm?37/52/38721\">",
"     picture 1",
"    </a>",
"    ). On cross-section, these tumors appear beefy red due to their high vascularity and contrast with any adjacent pale cerebellar tissue.",
"   </p>",
"   <p>",
"    Microscopically, the two main components of both sporadic and VHL-associated hemangioblastomas are an extensive vascular network and the neoplastic \"stromal cells\" (",
"    <a class=\"graphic graphic_picture graphicRef79080 \" href=\"UTD.htm?16/1/16407\">",
"     picture 2",
"    </a>",
"    ). The capillaries have a normal structure, including normal endothelial cells and pericytes. Neoplastic stromal cells, embedded among the vascular channels, have abundant cytoplasm packed with lipid vacuoles [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/14\">",
"     14",
"    </a>",
"    ]. The numerous lipid-containing vacuoles, which often impinge on the nucleus and scallop its edges, result in the typical \"clear cell\" morphology. These cells also have large nuclei that are often pleomorphic and hyperchromatic. Such nuclei are considered a degenerative feature rather than a sign of histologic grade, malignant potential or transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/15\">",
"     15",
"    </a>",
"    ]. The mitotic rate is typically low. Where the tumor borders brain, it often forms intertwined small nodules with the host tissue.",
"   </p>",
"   <p>",
"    Many of the clear-cell morphologic features of hemangioblastomas overlap with those of renal cell carcinomas (RCCs). RCCs, however, do not show the intimate relationship with the host tissue that can be found in a subset of hemangioblastomas, such at the intertwined nodules of brain, but instead have a border pushing against normal tissue. Since RCC is also a frequent manifestation of VHL disease and is histologically similar to hemangioblastomas, immunoperoxidase studies are often necessary to distinguish these tumors. Unlike RCCs, hemangioblastomas do not have an epithelial origin and so do not express cytokeratins or epithelial membrane antigen (EMA). Furthermore, hemangioblastomas typically display immunoreactivity to neuron specific enolase (NSE) unlike RCCs (",
"    <a class=\"graphic graphic_picture graphicRef69439 \" href=\"UTD.htm?9/23/9587\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinal angiomas are hemangioblastomas that develop in the retina and within the optic nerve. If left untreated, retinal hemangioblastomas can hemorrhage, leading to retinal detachment, glaucoma and loss of vision. Retinal angiomas are a frequent manifestation in patients with VHL disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Retinal capillary hemangioblastomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Molecular biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivation of the VHL tumor suppressor gene, located on chromosome 3p, is involved in the pathogenesis of some sporadic as well as VHL-associated hemangioblastomas. Somatic mutations of the VHL gene",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allelic deletion of the VHL gene may be present in as many as 50 percent of sporadic hemangioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Hemangioblastomas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetic changes are found in the stromal elements but not in the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/18,21\">",
"     18,21",
"    </a>",
"    ], suggesting that abnormal blood vessel formation might be caused by external factors produced by the stromal cells. In fact, expression of both erythropoietin and vascular endothelial growth factor (VEGF) is upregulated in the stromal cells of hemangioblastomas and may be involved in the pathogenesis of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas are highly vascular tumors that are often located in neurologically sensitive areas in the neuraxis (",
"    <a class=\"graphic graphic_picture graphicRef60110 \" href=\"UTD.htm?37/52/38721\">",
"     picture 1",
"    </a>",
"    ). The anatomic location of the lesion plays an important role in determining the therapeutic approach. Patients are best managed in a multidisciplinary fashion with input from neurosurgeons, interventional neuroradiologists, radiation oncologists, and neurooncologists with expertise in central nervous system malignancies.",
"   </p>",
"   <p>",
"    For patients with VHL disease, the frequent development of multiple lesions implies that therapeutic efforts should focus on avoiding treatment-related morbidity by minimizing the frequency of surgical interventions. Small asymptomatic lesions can be followed with careful surveillance. Although surgery can usually successfully remove lesions in the spinal cord, brainstem, and cerebellum, intervention is reserved until lesions become symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Patients who demonstrate progression by neural imaging should be followed at more frequent intervals for evidence of clinical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Hemangioblastomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with existing retinal, brain, and spinal cord lesions are at risk for tumor growth during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/27\">",
"     27",
"    </a>",
"    ]. A noncontrast MRI in the fourth month of pregnancy may be considered in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H9384234#H9384234\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Pregnancy and VHL'",
"    </a>",
"    .) Neuroimaging findings, along with clinical signs and symptoms, may be used to make decisions regarding the management of labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20634?source=see_link&amp;anchor=H17#H17\">",
"     \"Neurologic disorders complicating pregnancy\", section on 'Brain tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both surgical resection and radiation therapy have a role in the management of appropriately selected patients. However, there are no randomized clinical trials that compare these approaches, nor are there any randomized trials that address the optimal timing of therapeutic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection offers definitive therapy for sporadic, isolated hemangioblastomas, particularly those arising in the cerebellum. The role of surgery in patients with VHL disease is less well defined because of the frequent occurrence of additional synchronous and metachronous lesions.",
"   </p>",
"   <p>",
"    Hemangioblastomas are highly vascular, and patients frequently need a preoperative angiogram to identify feeding arteries. For large lesions, embolization of feeding arteries with polymer microspheres, ethanol, or polyvinyl alcohol particles is typically performed prior to surgery (",
"    <a class=\"graphic graphic_picture graphicRef55268 \" href=\"UTD.htm?1/47/1783\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Following preoperative embolization and using a microdissection technique with an intraoperative microscope, complete surgical resection of a hemangioblastoma is usually feasible with acceptable morbidity.",
"   </p>",
"   <p>",
"    The following contemporary series illustrate the outcomes following surgery for patients with hemangioblastomas in the cerebellum, spinal cord, and brainstem:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series from the National Institutes of Health (NIH), 80 patients with VHL underwent 126 operations, during which 164 cerebellar lesions were resected [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/32\">",
"       32",
"      </a>",
"      ]. Surgery was based upon the presence of symptoms (most frequently headache, ataxia, dysmetria, and hydrocephalus in 75, 55, 29, and 28 percent, respectively). Symptoms improved or stabilized in 98 percent of cases. Follow-up imaging at five years did not document any instances of recurrence.",
"     </li>",
"     <li>",
"      In a Japanese series, 40 of 48 VHL patients with hemangioblastomas of the spinal cord required surgery, including seven patients who required two operations [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/33\">",
"       33",
"      </a>",
"      ]. Among the 48 patients, 46 (96 percent) had associated central nervous system lesions, primarily in the cerebellum. Resection of the spinal tumors resulted in improvement or stabilization of symptoms in 39 of 47 cases (83 percent).",
"     </li>",
"     <li>",
"      In a French series, 34 patients (25 with VHL disease, 9 with sporadic lesions) underwent 40 operations, in which a total of 74 hemangioblastomas were resected [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/34\">",
"       34",
"      </a>",
"      ]. Tumors were located in the brainstem in 14 cases (19 percent) and the remainder were in the spinal cord, predominantly in the cervical and thoracic spine. At a mean follow-up of five years, 82 percent of patients were either improved or stabilized, while 18 percent were worse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal timing of surgery for patients with a hemangioblastoma is uncertain. The risks associated with operative management include intraoperative bleeding and postoperative neurologic complications.",
"   </p>",
"   <p>",
"    The consensus among most neurosurgeons is to follow these patients with surveillance MRI scans of the neuraxis. If there is progression of neurologic symptoms, evidence of tumor or cyst growth, neurologic deficit, or hemorrhage, operative intervention should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized clinical trials comparing radiation therapy (RT) to surgery in patients with hemangioblastomas, increasing data with relatively long follow-up support the role of RT, particularly for patients with multiple tumors and those with surgically inaccessible lesions. Most of the contemporary data come from series using stereotactic radiosurgery (SRS), although external beam RT or proton beam RT may be useful in selected cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contemporary series illustrating the outcomes following RT include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 31 patients (26 with VHL), 92 intracranial and spinal hemangioblastomas were treated with SRS [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/35\">",
"       35",
"      </a>",
"      ]. At a median follow-up of 69 months, 84 percent of tumors were either unchanged or smaller, and the five-year local control rate was 82 percent. Lesion-associated symptoms were improved in 36 of 41 evaluable cases (88 percent).",
"     </li>",
"     <li>",
"      In another series that included 32 patients (13 with VHL disease), 74 intracranial hemangioblastomas were treated with SRS [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/36\">",
"       36",
"      </a>",
"      ]. On follow-up imaging, tumor control was achieved for 68 tumors (92 percent). Progression-free survival at five years was 90 percent.",
"     </li>",
"     <li>",
"      In a series of 18 patients (five with VHL disease), 31 hemangioblastomas, including 20 in the cerebellum and 8 in the spinal cord, were treated with EBRT [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/695/abstract/37\">",
"       37",
"      </a>",
"      ]. Indications for therapy included recurrence after surgery, residual disease following surgery, or definitive therapy of the lesion in 12, 4, and 2 cases, respectively. With a median follow-up of five years, the five- and 10-year overall survival rates were 69 and 30 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antiangiogenic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the role of vascular endothelial growth factor in the formation of hemangioblastomas, inhibitors of angiogenesis may offer a potential therapeutic approach for lesions not amenable to surgery or radiation therapy. Preliminary experience with this approach has been derived from the treatment of patients with retinal angiomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Retinal capillary hemangioblastomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas are uncommon, slow-growing tumors of the central nervous system, which most commonly occur in the cerebellum, brainstem, or spinal cord. Hemangioblastomas occur both sporadically and as a component of von Hippel-Lindau (VHL) disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without VHL disease and with a single hemangioblastoma, we suggest surgery rather than observation both for treatment and to establish the diagnosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Radiation therapy is an option for recurrent or residual disease if the risk of reoperation is high. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients with a hemangioblastoma and without a history of VHL disease should be screened for VHL disease if they are relatively young or if they have other manifestations of VHL disease. Criteria for VHL screening are shown in the Table 1 (",
"      <a class=\"graphic graphic_table graphicRef66320 \" href=\"UTD.htm?12/45/13020\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sporadic versus VHL-associated tumors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Genetic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with known VHL disease who are asymptomatic and have imaging evidence of one or more hemangioblastomas, we suggest observation with serial imaging unless there is rapid tumor growth or symptoms develop, rather than immediate therapeutic intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Therapeutic intervention is indicated for patients with VHL disease and progressive symptoms. In this setting, we suggest surgical resection for accessible lesions and stereotactic radiosurgery for lesions that are not accessible or when the risk of postoperative neurologic deficits is high (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Sporadic versus VHL-associated tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/1\">",
"      Neumann HP, Eggert HR, Weigel K, et al. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg 1989; 70:24.",
"     </a>",
"    </li>",
"    <li>",
"     Aldape, KD, Plate, KH, Vortmeyer, AO, et al Haemangioblastoma. In Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee,WK (editors). WHO Classification of Tumours of the Nervous System. IARC Press, Lyon 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/3\">",
"      Roonprapunt C, Silvera VM, Setton A, et al. Surgical management of isolated hemangioblastomas of the spinal cord. Neurosurgery 2001; 49:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/4\">",
"      Wakai S, Inoh S, Ueda Y, Nagai M. Hemangioblastoma presenting with intraparenchymatous hemorrhage. J Neurosurg 1984; 61:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/5\">",
"      Adegbite AB, Rozdilsky B, Varughese G. Supratentorial capillary hemangioblastoma presenting with fatal spontaneous intracerebral hemorrhage. Neurosurgery 1983; 12:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/6\">",
"      Yu JS, Short MP, Schumacher J, et al. Intramedullary hemorrhage in spinal cord hemangioblastoma. Report of two cases. J Neurosurg 1994; 81:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/7\">",
"      Cerejo A, Vaz R, Feyo PB, Cruz C. Spinal cord hemangioblastoma with subarachnoid hemorrhage. Neurosurgery 1990; 27:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/8\">",
"      Kormos RL, Tucker WS, Bilbao JM, et al. Subarachnoid hemorrhage due to a spinal cord hemangioblastoma: case report. Neurosurgery 1980; 6:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/9\">",
"      WALDMANN TA, LEVIN EH, BALDWIN M. The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor. Am J Med 1961; 31:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/10\">",
"      Zec N, Cera P, Towfighi J. Extramedullary hematopoiesis in cerebellar hemangioblastoma. Neurosurgery 1991; 29:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/11\">",
"      K&uuml;hne M, Sidler D, Hofer S, et al. Challenging manifestations of malignancies. Case 1. Polycythemia and high serum erythropoietin level as a result of hemangioblastoma. J Clin Oncol 2004; 22:3639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/12\">",
"      Tachibana O, Yamashima T, Yamashita J. Immunohistochemical study of erythropoietin in cerebellar hemangioblastomas associated with secondary polycythemia. Neurosurgery 1991; 28:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/13\">",
"      Chu BC, Terae S, Hida K, et al. MR findings in spinal hemangioblastoma: correlation with symptoms and with angiographic and surgical findings. AJNR Am J Neuroradiol 2001; 22:206.",
"     </a>",
"    </li>",
"    <li>",
"     Bohling, T, Hatva, E, Plate, KH, et al. Von Hippel-Lindau disease and capillary haemangioblastoma. In: Tumor of the Nervous system Pathology and Genetics, Kleihues, P, Cavenee, WK (Eds) International Agency for Research on Cancer, Lyon, France 1997. p.179.",
"    </li>",
"    <li>",
"     Burger, PC, Scheithauer, BW. Tumors of the Central Nervous System. Armed Forces Institute of Pathology, Washington, DC 1994. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/16\">",
"      Omulecka A, Lach B, Alwasiak J, Gregor A. Immunohistochemical and ultrastructural studies of stromal cells in hemangioblastoma. Folia Neuropathol 1995; 33:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/17\">",
"      Kanno H, Kondo K, Ito S, et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54:4845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/18\">",
"      Lee JY, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998; 58:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/19\">",
"      Gl&auml;sker S, Bender BU, Apel TW, et al. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 2001; 70:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/20\">",
"      Gijtenbeek JM, Jacobs B, Sprenger SH, et al. Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg 2002; 97:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/21\">",
"      Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997; 28:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/22\">",
"      Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998; 92:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/23\">",
"      Conway JE, Chou D, Clatterbuck RE, et al. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001; 48:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/24\">",
"      Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/25\">",
"      Lonser RR, Weil RJ, Wanebo JE, et al. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/26\">",
"      Weil RJ, Lonser RR, DeVroom HL, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/27\">",
"      Frantzen C, Kruizinga RC, van Asselt SJ, et al. Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. Neurology 2012; 79:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/28\">",
"      Eskridge JM, McAuliffe W, Harris B, et al. Preoperative endovascular embolization of craniospinal hemangioblastomas. AJNR Am J Neuroradiol 1996; 17:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/29\">",
"      Tampieri D, Leblanc R, TerBrugge K. Preoperative embolization of brain and spinal hemangioblastomas. Neurosurgery 1993; 33:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/30\">",
"      Lonser RR, Heiss JD, Oldfield EH. Tumor devascularization by intratumoral ethanol injection during surgery. Technical note. J Neurosurg 1998; 88:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/31\">",
"      V&aacute;zquez-A&ntilde;&oacute;n V, Botella C, Beltr&aacute;n A, et al. Preoperative embolization of solid cervicomedullary junction hemangioblastomas: report of two cases. Neuroradiology 1997; 39:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/32\">",
"      Jagannathan J, Lonser RR, Smith R, et al. Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2008; 108:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/33\">",
"      Kanno H, Yamamoto I, Nishikawa R, et al. Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord 2009; 47:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/34\">",
"      Parker F, Aghakhani N, Ducati LG, et al. Results of microsurgical treatment of medulla oblongata and spinal cord hemangioblastomas: a comparison of two distinct clinical patient groups. J Neurooncol 2009; 93:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/35\">",
"      Moss JM, Choi CY, Adler JR Jr, et al. Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery 2009; 65:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/36\">",
"      Kano H, Niranjan A, Mongia S, et al. The role of stereotactic radiosurgery for intracranial hemangioblastomas. Neurosurgery 2008; 63:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/695/abstract/37\">",
"      Koh ES, Nichol A, Millar BA, et al. Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys 2007; 69:1521.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5209 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_695=[""].join("\n");
var outline_f0_43_695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sporadic versus VHL-associated tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Molecular biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antiangiogenic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5209|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/11/41136\" title=\"diagnostic image 1\">",
"      MRI cerebellar hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/57/36754\" title=\"diagnostic image 2\">",
"      MRI spinal hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5209|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/52/38721\" title=\"picture 1\">",
"      Spinal hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/1/16407\" title=\"picture 2\">",
"      Hemangiobl intraop smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/23/9587\" title=\"picture 3\">",
"      Hemangioblastoma NSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/47/1783\" title=\"picture 4\">",
"      Angiogram cerebellar hemangio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/45/13020\" title=\"table 1\">",
"      Screening von Hippel Lind",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=related_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20634?source=related_link\">",
"      Neurologic disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_43_696="Muscle biopsy polymyositis";
var content_f0_43_696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Interstitial inflammation in polymyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left panel) and high (right panel) views of muscle biopsy in polymyositis. There is an intense interstitial mononuclear infiltrate with some myocyte degeneration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD and William W Pendlebury, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_696=[""].join("\n");
var outline_f0_43_696=null;
var title_f0_43_697="Evaluation of acute pelvic pain in the adolescent female";
var content_f0_43_697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of acute pelvic pain in the adolescent female",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/697/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/697/contributors\">",
"     Kathleen Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/697/contributors\">",
"     June A Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/697/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/697/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/43/697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13206028\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of conditions can cause or contribute to pelvic pain in the adolescent female. Pelvic pain can be defined as any abdominal pain below the umbilicus, or lower abdominal pain. As a female enters adolescence and begins menstruation, the differential diagnosis of pelvic pain expands greatly.",
"   </p>",
"   <p>",
"    This topic will review the differential diagnosis and approach to the adolescent female presenting with pelvic pain with an emphasis on gynecologic conditions. The gastrointestinal and urologic causes of abdominal pain are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"     \"Causes of acute abdominal pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of acute pelvic pain in older women is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17095?source=see_link\">",
"     \"Evaluation of acute pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206035\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic pain most often involves the gastrointestinal or the urinary systems in prepubertal girls. However, gynecologic conditions become more prevalent as etiologies for pelvic pain, especially during late adolescence. The gynecologic causes of acute pelvic pain in adolescent females are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75310 \" href=\"UTD.htm?35/5/35931\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206042\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of pregnancy (eg, ectopic pregnancy, acute abruption, uterine rupture) comprise the most frequent life-threatening gynecologic causes of pelvic pain in adolescent females. Gastrointestinal causes of pelvic pain can be life-threatening if they lead to peritonitis and sepsis. Of these, appendicitis is most common and will be presented here. Other conditions (eg, abscess, bowel obstruction) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of acute abdominal pain in children and adolescents\", section on 'Life-threatening causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Life-threatening pelvic trauma in female adolescents is usually the result of a high-energy mechanism, such as a fall from a height or motor vehicle crash. Injury patterns and management are similar to the approach in adults and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H7#H7\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Fracture types'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H16#H16\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4155804\">",
"    <span class=\"h3\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients usually present with vaginal bleeding and crampy pelvic pain approximately six to eight weeks after the last menstrual period although later presentation is possible, especially if the pregnancy is not in the fallopian tube. Incidence is increased in those with a prior history of ectopic pregnancy, tubal surgery, and pelvic infection, along with those who use an intrauterine device for contraception.",
"    <strong>",
"    </strong>",
"    Rupture may initially bring temporary relief of pain; however, massive intraperitoneal hemorrhage may ensue with high maternal mortality soon after rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=see_link&amp;anchor=H3#H3\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4155837\">",
"    <span class=\"h3\">",
"     Placental abruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute, clinical abruption classically presents with vaginal bleeding, abdominal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    back pain, and uterine contractions. Peak incidence is between the 24",
"    <sup>",
"     th",
"    </sup>",
"    and 26",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation although placental abruption may occur at any time. The contractions are usually high frequency and low amplitude, but a mild to moderate contraction pattern is also possible. In the presence of a severe abruption (&ge;50 percent placental separation), both fetal and maternal compromise may occur. Acute disseminated intravascular coagulation (DIC) develops because blood is exposed to large amounts of tissue factor over a brief period of time. This exposure leads to massive generation of thrombin, resulting in the acute triggering of coagulation. The clinical consequence is a profound systemic bleeding diathesis in the mother and due to widespread intravascular fibrin deposition, tissue ischemic injury, and a microangiopathic hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link&amp;anchor=H5#H5\">",
"     \"Placental abruption: Clinical features and diagnosis\", section on 'Acute abruption'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4155912\">",
"    <span class=\"h3\">",
"     Uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of uterine rupture can include nonreassuring fetal heart rate tracing or fetal death, uterine tenderness, peritoneal irritation, vaginal bleeding, loss of fetal station, and shock. Most uterine ruptures occur in laboring women with a prior cesarean delivery or prior uterine surgery. Rupture of the unscarred uterus during labor is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36554?source=see_link&amp;anchor=H2677735#H2677735\">",
"     \"Approach to abdominal pain and the acute abdomen in pregnant and postpartum women\", section on 'Uterine rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206049\">",
"    <span class=\"h3\">",
"     Appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute appendicitis is the most common cause for emergent abdominal surgery in children; incidence increases with age and peaks in adolescence. Initial periumbilical pain, which later localizes to the area of peritoneal irritation, usually the right lower quadrant, followed by fever, vomiting, and anorexia is the most common presentation. Obstruction of the appendiceal lumen can lead to thrombosis, necrosis, and if untreated, perforation. Complications involve ileus, abscess formation, intestinal obstruction, peritonitis, sepsis, and shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3093327\">",
"    <span class=\"h3\">",
"     Ovarian torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian torsion refers to twisting of the adnexa upon its pedicle and typically presents with an acute onset of sharp, intermittent abdominal pain associated with nausea and vomiting. Formation of ovarian cysts may predispose to torsion, and therefore, torsion has a higher incidence in adolescents than prepubertal girls. This condition requires prompt surgical intervention to prevent necrosis and loss of the ovary. Although typically not life-threatening, ovarian torsion does present a significant risk to future fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link&amp;anchor=H327710#H327710\">",
"     \"Ovarian and fallopian tube torsion\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206084\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysmenorrhea is the most common gynecologic cause of pelvic pain during adolescence. Pelvic inflammatory disease and mittelschmerz are also frequent. Urinary tract infections (cystitis, pyelonephritis) are very common causes of lower abdominal pain. Nephrolithiasis is an increasingly common cause of pelvic pain in adolescents. Other common urologic etiologies (eg, urinary tract infection) as well as gastrointestinal conditions (eg, constipation, gastrointestinal infection, functional abdominal pain) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of acute abdominal pain in children and adolescents\", section on 'Common causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Functional disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4156466\">",
"    <span class=\"h3\">",
"     Dysmenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual",
"    <strong>",
"    </strong>",
"    pain affects at least two-thirds of postmenarchal females in the United States, some of whom experience severe pain sufficient to affect daily activities. Dysmenorrhea is",
"    <strong>",
"    </strong>",
"    usually crampy and intermittent. Nausea, vomiting,",
"    <strong>",
"    </strong>",
"    diarrhea, headache, dizziness, or back pain may accompany the crampy abdominal pain. The pain and associated symptoms typically begin several hours prior to the onset",
"    <strong>",
"    </strong>",
"    of menstruation and continue for one to three days. The severity of the disorder can be categorized by a grading system based upon the degree of menstrual pain, presence of systemic symptoms, and impact on daily activities (",
"    <a class=\"graphic graphic_table graphicRef65347 \" href=\"UTD.htm?22/16/22795\">",
"     table 2",
"    </a>",
"    )",
"    <strong>",
"     .",
"    </strong>",
"    Dysmenorrhea can be divided into primary causes (absence of any pelvic pathology and the more common form which typically begins during adolescence) or secondary causes (underlying pelvic pathology, such as endometriosis).",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary dysmenorrhea in adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4156418\">",
"    <span class=\"h3\">",
"     Mittelschmerz",
"    </span>",
"    &nbsp;&mdash;&nbsp;This ovulatory event causes recurrent midcycle pain in females with regular ovulatory cycles. This pain is caused by normal follicular enlargement just prior to ovulation or to normal follicular bleeding at ovulation. The pain is typically mild and unilateral; it occurs midway between menstrual periods and lasts for a few hours to a couple of days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of ruptured ovarian cyst\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4156366\">",
"    <span class=\"h3\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID) is most commonly caused by C. trachomatis and N. gonorrhoeae, both of which have the highest prevalence in the adolescent population. PID is an infection of the upper genital tract in females and includes endometritis, salpingitis, tubo-ovarian abscess, and pelvic peritonitis.",
"   </p>",
"   <p>",
"    Lower abdominal pain is the cardinal presenting symptom in adolescents with PID, although the character of the pain may be quite subtle. The recent onset of pain that worsens during coitus or with jarring movement may be the only presenting symptom of PID; the onset of pain during or shortly after menses is particularly suggestive. About half of patients with PID have fever. On pelvic examination, the findings of a purulent endocervical discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute cervical motion and adnexal tenderness with bimanual examination are strongly suggestive of the diagnosis. Additional nonspecific symptoms may include abnormal vaginal bleeding, dysmenorrhea, vaginal discharge, or gastrointestinal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4156405\">",
"    <span class=\"h3\">",
"     Ruptured ovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ovarian cyst that ruptures can cause sudden, severe, unilateral pelvic pain without fever or any gastrointestinal, urinary, or vaginal symptoms. Historically, they occur preceding a menstrual period. The pain often begins during strenuous physical activity, such as exercise or sexual intercourse. Blood from the rupture site may seep into the ovary, which can cause pain from stretching of the ovarian cortex, or it may flow into the abdomen, which has an irritant effect on the peritoneum. Significant hemorrhage leading to shock is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of ruptured ovarian cyst\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4156549\">",
"    <span class=\"h3\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney stones, an increasingly common cause of pelvic pain in adolescents, typically presents with intense, paroxysmal flank pain, which may radiate",
"    <strong>",
"    </strong>",
"    to the lower abdomen and groin regions. The pain is usually colicky and causes the patient to writhe about because they are unable to find a position of comfort. Nausea, vomiting, and urinary symptoms may accompany the pain. The diagnosis of nephrolithiasis is initially suspected by the presentation and clinical evaluation (including urinalysis). It is confirmed by the detection of a stone on imaging studies or by retrieval of a passed stone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of nephrolithiasis in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832927\">",
"    <span class=\"h3\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic cystitis causes suprapubic pain and dysuria. Fever, urinary frequency, and urinary hesitancy may also be present. Pyelonephritis frequently presents with fever, vomiting, flank, and upper back pain. Symptoms of cystitis may also be present. Rapid urine dipstick tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microscopic urinalysis establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Older children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206115\">",
"    <span class=\"h2\">",
"     Other gynecologic conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pregnancy",
"      </strong>",
"      &ndash; Intrauterine pregnancy is the most common diagnosis for the presentation of secondary amenorrhea. Other common symptoms include morning sickness, breast tenderness, urinary frequency, weight gain, fatigue, and abdominal pain. Pelvic pain is an uncommon primary presenting symptom for pregnancy, although round ligament pain, pubic symphysis separation, or pelvic girdle pain (sacroiliac joint pain) is relatively common. Care must be taken not to miss other causes of pelvic pain (eg, appendicitis, ovarian torsion) in pregnant females. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=see_link&amp;anchor=H12#H12\">",
"       \"Musculoskeletal changes and pain during pregnancy and postpartum\", section on 'Pregnancy related pelvic joint pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Spontaneous abortion",
"      </strong>",
"      &ndash; Abortion is the outcome of at least 20 percent of all pregnancies, presenting with crampy pelvic pain, vaginal bleeding, and passage of some or all of the products of conception. In the face of a nonsterile abortive procedure or incomplete evacuation of all fetal and placental tissue, sepsis may develop. Clinical findings of a septic abortion include fever, diffuse pelvic pain, and malodorous vaginal discharge. Complications, such as septic shock and rarely, pelvic thrombophlebitis, can occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link&amp;anchor=H24#H24\">",
"       \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Clinical manifestation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Developmental anomalies of the M&uuml;llerian duct",
"      </strong>",
"      &ndash; Anomalies of the M&uuml;llerian duct may cause pelvic pain that first presents at puberty. Of these anomalies, imperforate hymen",
"      <strong>",
"      </strong>",
"      is the most common outflow tract obstruction, and it is most often diagnosed at puberty when menstrual fluid collects. Imperforate hymen can cause primary amenorrhea, a pelvic mass, hydrometrocolpos (dilatation of the uterus and vagina), and pelvic pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link&amp;anchor=H9#H9\">",
"       \"Diagnosis and management of congenital anomalies of the vagina\", section on 'Anomalies of the hymen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Endometriosis",
"      </strong>",
"      &ndash; Endometrial tissue found outside of the uterus in ectopic locations can cause crampy pelvic pain associated with menses. It has even been known to cause painful defecation and dyspareunia, depending on its location. Though more commonly found in adult women, detection of endometriosis in adolescents is increasing and should be included in the differential. Early diagnosis may impact disease progression and long-term prognosis, especially concerning fertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H21#H21\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Adolescents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Reproductive organ and vulvar tumors",
"      </strong>",
"      &ndash; Neoplasm is rare in the pediatric population, but includes ovarian, uterine, cervical, vaginal, and even vulvar disease. Ovarian tumors occur in approximately 2 percent of adolescents and young adult women. Germ cell tumors are the most common histologically, and the most common of these is the dermoid cyst, or mature cystic teratoma, a benign neoplastic cyst. These tumors contain ectodermal, mesodermal, and endodermal tissue (ie, hair, bone, teeth, brain, adipose tissue, skin, etc). They can present with dull abdominal pain or a mass, but they are frequently asymptomatic and found incidentally on imaging due to calcification or increased echogenicity. They may be bilateral in 7 percent of adolescents. They may also increase the risk of ovarian torsion, and approximately 1 to 3 percent can rupture. There are numerous other malignancies, and though rare, several peak during adolescence, such as immature teratomas, endodermal sinus tumors, mixed germ cell tumors, and gonadoblastoma. These usually present with pelvic pain, a palpable mass, or abdominal distention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"       \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vaginal foreign bodies",
"      </strong>",
"      &ndash; Foreign bodies include \"lost\" intrauterine devices, contraceptive rings, condoms, tampons, or other objects intentionally placed in the vaginal cavity. Pelvic pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      purulent vaginal discharge can rarely ensue, especially if significant vaginal wall irritation or trauma ensues. Complications, such as abscess formation or vaginal or uterine perforation, rarely occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"       \"Approach to women with symptoms of vaginitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chemical irritants",
"      </strong>",
"      &ndash; Spermicides, lubricants, douching material, or bath products may cause vaginal irritation and pelvic pain. Douching predisposes to bacterial vaginosis and is not necessary for good vulvovaginal hygiene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link&amp;anchor=H1860693#H1860693\">",
"       \"Approach to women with symptoms of vaginitis\", section on 'Irritants and allergens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual assault",
"      </strong>",
"      &ndash; Pelvic pain may indicate vaginal contusions, bruising, laceration or perforation in adolescents who have been sexually assaulted. The breasts, external genitalia, anus, and rectum should also be carefully examined for signs of injury. Detectable trauma is more likely in adolescent females who are virginal or report vaginal or anal penetration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation and management of adult sexual assault victims\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual abuse",
"      </strong>",
"      &ndash; The possibility of abuse, recent or past, absolutely must be included in any differential of acute or chronic pelvic pain. Previous psychological trauma, such as emotional, physical, or sexual abuse, can manifest itself as chronic functional pelvic pain. Depression, as a result of abuse or as a separate disease in itself, may be associated with chronic pelvic pain as well [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/697/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Somaticization",
"      </strong>",
"      &ndash; Feigned symptoms",
"      <strong>",
"      </strong>",
"      should be considered in the absence of organic disease and an inconsistent historical and clinical picture. Psychosocial issues should be investigated, as well as any concern for abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H7#H7\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1119600\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first goal of the evaluation of the adolescent female with pelvic pain is to identify life-threatening conditions that require emergent interventions. Once this has been accomplished, other causes of pelvic pain can often be identified through deliberate evaluation with careful attention to the clinical features of the illness (eg, the pain characteristics, sexual history, presence of pregnancy, related symptoms, physical findings, and selected diagnostic studies) (",
"    <a class=\"graphic graphic_algorithm graphicRef58054 \" href=\"UTD.htm?20/40/21134\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef69761 \" href=\"UTD.htm?8/28/8654\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef63401 \" href=\"UTD.htm?2/55/2943\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef77147 \" href=\"UTD.htm?2/56/2944\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The evaluation for gastrointestinal and urologic causes of pelvic pain is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link&amp;anchor=H3#H3\">",
"     \"Emergent evaluation of the child with acute abdominal pain\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206162\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain characteristics, associated symptoms, menstrual status, and sexual history help to differentiate among the various gynecologic causes of pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/697/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pain characteristics",
"      </strong>",
"      &ndash; The clinician should determine the pain location, quality, radiation, timing, and associated symptoms, including temporal association with the menstrual cycle. Suggestive pain patterns include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Ectopic pregnancy",
"      </strong>",
"      &ndash; Lower abdominal pain, typically six to eight weeks after the last menstrual period, often lateralizing, with symptoms of pregnancy, syncope and vaginal bleeding; with intraperitoneal bleeding, irritation of the diaphragm with referred pain to the shoulder or pooling of blood in the posterior cul-de-sac (pouch of Douglas) with an urge to defecate may occur (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'History'",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Ovarian torsion",
"      </strong>",
"      &ndash; Abrupt onset of stabbing pain in the lower abdomen, typically lateralizing, with radiation to the back, flank, or groin and associated with nausea and vomiting (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link&amp;anchor=H327710#H327710\">",
"       \"Ovarian and fallopian tube torsion\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Ruptured ovarian cyst",
"      </strong>",
"      &ndash; Sudden onset of lateralizing pain, especially in association with exercise or sexual intercourse (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation and management of ruptured ovarian cyst\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Pelvic inflammatory disease",
"      </strong>",
"      &ndash; Bilateral pain commonly occurring during or just after menses that is worsened by coitus or jarring movement and occasionally associated with a new vaginal discharge, fever, or dysuria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Dysmenorrhea",
"      </strong>",
"      &ndash; Midline, cramping or dull pain associated with menstruation and often accompanied by back pain, fatigue, headache, nausea, vomiting, or diarrhea (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=see_link&amp;anchor=H7#H7\">",
"       \"Primary dysmenorrhea in adolescents\", section on 'Typical symptoms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Mittelschmerz",
"      </strong>",
"      &ndash; Mild to moderate constant lateralizing pain occurring midway between menstrual periods",
"     </li>",
"     <li>",
"      <strong>",
"       Placental abruption",
"      </strong>",
"      &ndash; Lower abdominal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      back pain, typically in the second or third trimester of pregnancy with vaginal bleeding and high frequency and low amplitude contractions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link&amp;anchor=H5#H5\">",
"       \"Placental abruption: Clinical features and diagnosis\", section on 'Acute abruption'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Menstrual status",
"      </strong>",
"      &ndash; It must be ascertained early on whether the adolescent in question is pre or postmenarchal. In postmenarchal females, the timing of the last menstrual period should be determined in relation to the onset of pain and to evaluate for possible pregnancy.",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual history",
"      </strong>",
"      &mdash; Sexually active adolescents are at risk for complications of pregnancy and pelvic inflammatory disease. It is important to have a nonjudgmental approach to obtaining a sexual history from the adolescent patient in order to protect her confidentiality and to maximize the likelihood that her responses will be truthful:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Questions about whether an adolescent has had sexual intercourse should only be posed when the patient's parent or guardian is not present.",
"     </li>",
"     <li>",
"      The clinician should introduce these questions with both an assurance that she or he will protect the teenager's confidentiality and a mention of any exceptions to confidentiality. State and federal laws and regulations in the United States and in other countries can limit confidentiality in specific circumstances, such as pregnancy in a minor, suicidality, and situations in which the teenager is in the legal custody of a state agency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=see_link\">",
"       \"Consent in adolescent health care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For every patient who has had sexual intercourse, questions should focus on the use of contraceptive methods and difficulty with contraceptive use (missed contraceptive pills, broken or unused condom, etc).",
"     </li>",
"     <li>",
"      Other key information includes the timing of the last intercourse, any history of sexually transmitted diseases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvic inflammatory disease, and any prior pregnancies.",
"     </li>",
"     <li>",
"      Patients who disclose sexual assault should ideally have the remainder of the evaluation performed by providers specifically trained to care for such cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation and management of adult sexual assault victims\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206225\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adolescent female with pelvic pain warrants a complete examination with particular focus on vital signs and examination of the abdomen, genitalia, and pelvis. Hemodynamically unstable patients require resuscitation of shock prior to a comprehensive physical examination (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial management of shock in children\", section on 'Early goal-directed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vital signs",
"      </strong>",
"      &ndash; Fever suggests the presence of appendicitis, pelvic inflammatory disease (PID), or rarely, a septic abortion. Tachycardia with poor capillary perfusion or hypotension suggests shock in association with acute abruption, ectopic pregnancy, uterine rupture, appendicitis, ruptured hemorrhagic ovarian cyst (rare), or septic abortion.",
"     </li>",
"     <li>",
"      <strong>",
"       Abdomen",
"      </strong>",
"      &ndash; Right lower quadrant tenderness may arise from appendicitis, pelvic inflammatory disease, ovarian torsion, ovarian cyst, ectopic pregnancy, or nephrolithiasis. Left lower quadrant tenderness is caused by the same diagnoses, although appendicitis occurs rarely on the left side. Bilateral lower quadrant tenderness suggests PID. Rebound tenderness is found in patients with appendicitis or PID. A midline tender mass may be appreciated in adolescents females with imperforate hymen and hydrometrocolpos. Other causes of abdominal pain in the adolescent female are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"       \"Causes of acute abdominal pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pelvic examination",
"      </strong>",
"      &ndash; A pelvic examination is essential in all sexually active adolescent females with pelvic pain. A speculum examination is necessary to assess for cervical discharge or bleeding and to evaluate for vaginal laceration or abnormal discharge. Cervical specimens for N. gonorrhoeae and Chlamydia trachomatis should be obtained and a sample of vaginal discharge collected for microscopic examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to women with symptoms of vaginitis\", section on 'Diagnostic studies'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although a vaginal bimanual examination is preferred, a rectal bimanual examination may be substituted in virginal patients.",
"      <br/>",
"      <br/>",
"      Important findings on pelvic examination may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Imperforate hymen (hematometrocolpos)",
"     </li>",
"     <li>",
"      Vulvar, anal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vaginal trauma (sexual assault)",
"     </li>",
"     <li>",
"      Vaginal discharge (PID)",
"     </li>",
"     <li>",
"      Vaginal bleeding (ectopic pregnancy, acute abruption, spontaneous abortion, normal labor)",
"     </li>",
"     <li>",
"      Cervical motion tenderness (PID)",
"     </li>",
"     <li>",
"      Uterine tenderness (PID, acute abruption, dysmenorrhea, uterine rupture)",
"     </li>",
"     <li>",
"      Adnexal tenderness (PID, ectopic pregnancy, ovarian torsion)",
"     </li>",
"     <li>",
"      Adnexal mass (ovarian mass [cyst, abscess, or tumor], ectopic pregnancy, PID, endometriosis)",
"     </li>",
"     <li>",
"      Tenderness of the posterior cul-de-sac, rectovaginal septum, or uterosacral ligaments on rectovaginal examination (endometriosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206274\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination direct the subsequent ancillary testing that should be done.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pregnancy test",
"      </strong>",
"      &ndash; Urine pregnancy testing must be done in a menstruating adolescent, and may also be appropriate in the ostensibly premenstrual girl in the face of an ambiguous history or clinical picture. Urine beta human chorionic gonadotropin testing is rapid and sensitive for detecting early pregnancy. If the patient is pregnant, quantitative beta hCG testing and Rh(D) typing may be indicated and the status of the pregnancy should be determined (eg, ectopic, intrauterine, threatened abortion). It is important to keep in mind that a positive pregnancy test does not exclude a non-gynecologic cause of pelvic pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link&amp;anchor=H8967182#H8967182\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\", section on 'Urine pregnancy test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urine tests",
"      </strong>",
"      &ndash; After cleansing, a rapid urine dipstick that indicates hematuria or pyuria helps to identify those patients that should have a microscopic urinalysis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine culture. Of note, bladder catheterization is typically needed in patients with vaginal bleeding to avoid contamination of the urine specimen.",
"     </li>",
"     <li>",
"      <strong>",
"       Complete blood count and inflammatory markers",
"      </strong>",
"      &ndash; Patients with pelvic pain who have vaginal bleeding warrant assessment for anemia and thrombocytopenia. An elevated white blood cell count with immature neutrophil forms on differential is suggestive of appendicitis or pelvic inflammatory disease. Erythrocyte sedimentation rates or C-reactive protein levels may also be increased in patients with these conditions. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Blood typing &ndash;",
"      </strong>",
"      Pregnant patients with spontaneous abortion, ectopic pregnancy or placental abruption should have blood typing to determine Rh (D or Rhesus antigen) status and the potential need for anti-D immune globulin administration to prevent alloimmunization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"       \"Prevention of Rh(D) alloimmunization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link&amp;anchor=H8#H8\">",
"       \"Prevention of Rh(D) alloimmunization\", section on 'Additional indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Detection of sexually transmitted disease",
"      </strong>",
"      &ndash; Depending upon clinical suspicion, cervical culture (gonorrhea, chlamydia, genital herpes, Trichomonas), serology (herpes simplex virus type 2, syphilis), or cervical nucleic acid amplification tests (N. gonorrhoeae, C. trachomatis) or a combination may be obtained. Alternatively, nucleic acid amplification tests for C. trachomatis and N. gonorrhoeae may be sent on a spontaneously voided urine obtained before external cleansing in patients for whom pelvic examination is otherwise unnecessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H16#H16\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Screening and diagnostic testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1120299\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound (US) is the preferred initial method for evaluating pelvic pathology. The ultrasound examination is usually initiated transabdominally. The bladder does not have to be full; however, if the ovaries cannot be visualized, it may be necessary to have the patient fill her bladder to a comfortable capacity. This is especially important for those teenagers who are unable to tolerate placement of a transvaginal ultrasound probe. Often in these cases, the entire examination can be performed transabdominally. Transabdominal scanning is important for evaluating the upper pelvis and abdomen, and can detect appendicitis, in some cases, nephrolithiasis, ovarian cysts, tumors, and tuboovarian abscess. Doppler flow studies can assist in the urgent diagnosis of ovarian torsion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=see_link&amp;anchor=H22#H22\">",
"     \"Ultrasound examination in obstetrics and gynecology\", section on 'Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19416?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute appendicitis in children: Diagnostic imaging\", section on 'Ultrasonography (US)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transvaginal sonography is best performed with an empty bladder and is helpful in diagnosing ectopic and intrauterine pregnancy and spontaneous abortion.",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the abdomen and pelvis may be helpful in patients in whom diagnostic uncertainty persists after laboratory and US evaluation, especially those in whom nephrolithiasis or appendicitis is suspected. Contrast should not be given to patients undergoing CT for the diagnosis of nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of nephrolithiasis in children\", section on 'Non-contrast helical CT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19416?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute appendicitis in children: Diagnostic imaging\", section on 'Computed tomography (CT)'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Rarely, magnetic resonance imaging may be helpful in patients with suspected malformations of the genitourinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1120387\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy is sometimes indicated in the evaluation of acute pelvic pain, especially when the diagnosis is not clear after less invasive evaluations and the differential diagnoses include potentially life-threatening or organ-threatening disorders. Examples are appendicitis, pelvic inflammatory disease, endometriosis, and ovarian torsion. Laparoscopy also has a role in the treatment of many surgical disorders. On the other hand, most adolescent females with acute pelvic pain, normal imaging and laboratory studies, and a normal physical examination (including absence of",
"    <span class=\"nowrap\">",
"     vaginal/cervical",
"    </span>",
"    discharge and abnormal uterine bleeding) will improve without need for intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17095?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation of acute pelvic pain in women\", section on 'Laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206372\">",
"    <span class=\"h1\">",
"     ALGORITHMIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5587293\">",
"    <span class=\"h2\">",
"     Pregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the pregnant adolescent female with pelvic pain is show in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef58054 \" href=\"UTD.htm?20/40/21134\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef69761 \" href=\"UTD.htm?8/28/8654\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5587309\">",
"    <span class=\"h3\">",
"     Vaginal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant patients with vaginal bleeding first should be assessed for hemodynamic stability (",
"    <a class=\"graphic graphic_algorithm graphicRef58054 \" href=\"UTD.htm?20/40/21134\">",
"     algorithm 1",
"    </a>",
"    ). Shock is associated with a ruptured ectopic pregnancy, acute abruption, and uterine rupture. Patients who are less than 20 weeks gestation and hemodynamically stable may have abruptio placenta or a spontaneous abortion. In addition to these conditions, those patients with vaginal bleeding during late pregnancy may be in normal or premature labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5587317\">",
"    <span class=\"h3\">",
"     No vaginal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant patients without vaginal bleeding, but with rhythmic contractions may be in normal or premature labor (late pregnancy by examination or ultrasound) or may have a threatened abortion (",
"    <a class=\"graphic graphic_algorithm graphicRef69761 \" href=\"UTD.htm?8/28/8654\">",
"     algorithm 2",
"    </a>",
"    ). Patients with sacroiliac joint pain with provocative testing (FABERE sign) may have pelvic girdle pain of pregnancy. Otherwise, the clinician should evaluate for causes unrelated to pregnancy, especially in patients with fever or peritonitis (",
"    <a class=\"graphic graphic_algorithm graphicRef69041 \" href=\"UTD.htm?1/2/1058\">",
"     algorithm 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5587301\">",
"    <span class=\"h2\">",
"     Not pregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to pelvic pain in the adolescent female who is not pregnant is shown in the algorithms and varies according to whether the girl has reached normal menstruation or not (",
"    <a class=\"graphic graphic_algorithm graphicRef63401 \" href=\"UTD.htm?2/55/2943\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef77147 \" href=\"UTD.htm?2/56/2944\">",
"     algorithm 4",
"    </a>",
"    ). A careful physical examination with selected ancillary studies helps differentiate among the possible causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29078100\">",
"    <span class=\"h3\">",
"     Premenarchal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key findings for girls who have not yet reached normal menstruation include (",
"    <a class=\"graphic graphic_algorithm graphicRef63401 \" href=\"UTD.htm?2/55/2943\">",
"     algorithm 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual assault may be determined by history or diagnosed by evidence of vulvovaginal trauma.",
"     </li>",
"     <li>",
"      Hydrocolpos with an imperforate hymen is identified on external examination of the vulva.",
"     </li>",
"     <li>",
"      Right lower quadrant tenderness with supportive findings on complete blood count",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound suggests appendicitis.",
"     </li>",
"     <li>",
"      Flank pain radiating to the pelvis with hematuria is found in patients with nephrolithiasis.",
"     </li>",
"     <li>",
"      Flank or suprapubic pain with pyuria suggests pyelonephritis or a urinary tract infection.",
"     </li>",
"     <li>",
"      Rarely, a previously premenarchal girl may be pregnant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29944782\">",
"    <span class=\"h3\">",
"     Postmenarchal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In females who have reached normal menstruation, the diagnosis is suggested by the following clinical findings (",
"    <a class=\"graphic graphic_algorithm graphicRef77147 \" href=\"UTD.htm?2/56/2944\">",
"     algorithm 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A vaginal foreign body is typically evident on pelvic examination.",
"     </li>",
"     <li>",
"      Vaginal bleeding with pain during menstruation is seen in patients with dysmenorrhea.",
"     </li>",
"     <li>",
"      Bilateral adnexal tenderness with cervical discharge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cervical motion tenderness supports the diagnosis of pelvic inflammatory disease.",
"     </li>",
"     <li>",
"      Patients with unilateral stabbing abdominal pain and decreased blood flow by Doppler ultrasound (US) have ovarian torsion.",
"     </li>",
"     <li>",
"      An adnexal mass on pelvic examination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound is seen in patients with ovarian tumor, abscess, or cyst.",
"     </li>",
"     <li>",
"      Endometriosis is suggested by recurrent pain, dyspareunia, or typical findings on recto-vaginal examination. (See",
"      <a class=\"local\" href=\"#H13206225\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are midcycle and have lateral pain without any other distinguishing features likely have mittelschmerz.",
"     </li>",
"     <li>",
"      If the evaluation, including pelvic examination, urinalysis, complete blood count, and ultrasound fail to establish a diagnosis in a menstruating female, then the clinician should observe for additional signs of appendicitis or PID and pursue other gastrointestinal or urologic causes (",
"      <a class=\"graphic graphic_algorithm graphicRef69041 \" href=\"UTD.htm?1/2/1058\">",
"       algorithm 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1120584\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic pain most often involves the gastrointestinal or the urinary systems in prepubertal girls. However, gynecologic conditions become more prevalent as etiologies for pelvic pain, especially during late adolescence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gynecologic causes of acute pelvic pain in adolescent females are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef75310 \" href=\"UTD.htm?35/5/35931\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13206035\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain characteristics, associated symptoms, menstrual status, and sexual history help to differentiate among the various gynecologic causes of pelvic pain. (See",
"      <a class=\"local\" href=\"#H13206162\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The adolescent female with pelvic pain warrants a complete examination with particular focus on vital signs and examination of the abdomen, genitalia, and pelvis. Hemodynamically unstable patients require resuscitation of shock prior to a comprehensive physical examination (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"       algorithm 5",
"      </a>",
"      ). A pelvic examination is essential in all sexually active adolescent females with pelvic pain. (See",
"      <a class=\"local\" href=\"#H13206225\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urine pregnancy testing must be done in a menstruating adolescent and may also be appropriate in the ostensibly premenstrual girl in the face of an ambiguous history or clinical picture. Other ancillary studies are guided by clinical findings. (See",
"      <a class=\"local\" href=\"#H13206274\">",
"       'Laboratory'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1120299\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The algorithms provide a suggested approach to adolescent with pelvic pain according to the presence of key findings, such as vaginal bleeding, pregnancy, and other results of clinical evaluation (",
"      <a class=\"graphic graphic_algorithm graphicRef58054 \" href=\"UTD.htm?20/40/21134\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef69761 \" href=\"UTD.htm?8/28/8654\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef63401 \" href=\"UTD.htm?2/55/2943\">",
"       algorithm 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef77147 \" href=\"UTD.htm?2/56/2944\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13206372\">",
"       'Algorithmic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/697/abstract/1\">",
"      Berkowitz CD. Medical consequences of child sexual abuse. Child Abuse Negl 1998; 22:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/697/abstract/2\">",
"      Kamm MA. Chronic pelvic pain in women--gastroenterological, gynaecological or psychological? Int J Colorectal Dis 1997; 12:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/697/abstract/3\">",
"      Kruszka PS, Kruszka SJ. Evaluation of acute pelvic pain in women. Am Fam Physician 2010; 82:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/697/abstract/4\">",
"      Hewitt GD, Brown RT. Acute and chronic pelvic pain in female adolescents. Med Clin North Am 2000; 84:1009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13889 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_697=[""].join("\n");
var outline_f0_43_697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1120584\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13206028\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13206035\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206042\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4155804\">",
"      - Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4155837\">",
"      - Placental abruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4155912\">",
"      - Uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13206049\">",
"      - Appendicitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3093327\">",
"      - Ovarian torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206084\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4156466\">",
"      - Dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4156418\">",
"      - Mittelschmerz",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4156366\">",
"      - Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4156405\">",
"      - Ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4156549\">",
"      - Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832927\">",
"      - Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206115\">",
"      Other gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1119600\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206162\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206225\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206274\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1120299\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1120387\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13206372\">",
"      ALGORITHMIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5587293\">",
"      Pregnant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5587309\">",
"      - Vaginal bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5587317\">",
"      - No vaginal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5587301\">",
"      Not pregnant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29078100\">",
"      - Premenarchal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29944782\">",
"      - Postmenarchal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1120584\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13889|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/40/21134\" title=\"algorithm 1\">",
"      Pelvic pain in the pregnant adolescent female with vaginal bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/28/8654\" title=\"algorithm 2\">",
"      Pelvic pain in the pregnant adolescent female with no bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/55/2943\" title=\"algorithm 3\">",
"      Acute pelvic pain in the premenarchal adolescent female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/56/2944\" title=\"algorithm 4\">",
"      Acute pelvic pain in the postmenarchal adolescent female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/12/42178\" title=\"algorithm 5\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/2/1058\" title=\"algorithm 6\">",
"      Algorithm - acute abdominal pain postmenarchal girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/5/35931\" title=\"table 1\">",
"      Gynecologic causes of acute pelvic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/16/22795\" title=\"table 2\">",
"      Scoring system for dysmenorrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19416?source=related_link\">",
"      Acute appendicitis in children: Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36554?source=related_link\">",
"      Approach to abdominal pain and the acute abdomen in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=related_link\">",
"      Causes of acute abdominal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=related_link\">",
"      Clinical features and diagnosis of nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17095?source=related_link\">",
"      Evaluation of acute pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=related_link\">",
"      Musculoskeletal changes and pain during pregnancy and postpartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=related_link\">",
"      Primary dysmenorrhea in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_43_698="Alcoholic hepatitis: Natural history and management";
var content_f0_43_698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alcoholic hepatitis: Natural history and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/698/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/698/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/43/698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/43/698/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/43/698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H234083145\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive alcohol consumption is associated with a range of hepatic manifestations, including alcoholic fatty liver disease (with or without steatohepatitis), alcoholic hepatitis, and cirrhosis. While asymptomatic steatohepatitis due to alcohol could be referred to as \"alcoholic hepatitis\", the term is typically used to describe the acute onset of symptomatic hepatitis. The amount of alcohol intake that puts an individual at risk for alcoholic hepatitis is not known, but the majority of patients have a history of heavy alcohol use (more than 100",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    for two or more decades (",
"    <a class=\"graphic graphic_figure graphicRef68118 \" href=\"UTD.htm?4/61/5079\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the prognosis and management of patients with alcoholic hepatitis. The pathogenesis of alcoholic liver disease, the clinical manifestations and diagnosis of alcoholic hepatitis, and the approach to patients with alcoholic fatty liver disease or alcoholic cirrhosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/AlcoholicLiverDisease1-2010.pdf\">",
"     Guidelines",
"    </a>",
"    for the management of patients with alcoholic liver disease were issued in 2010 by the American Association for the Study of Liver Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/3\">",
"     3",
"    </a>",
"    ]. The discussion that follows is generally consistent with those guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081660\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates among patients who do not receive pharmacologic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) for alcoholic hepatitis are variable. In patients with severe alcoholic hepatitis (typically defined by a Maddrey discriminant function &ge;32 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"     calculator 1",
"    </a>",
"    )), short-term mortality rates are high (approximately 25 to 35 percent at one month) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], whereas patients with mild to moderate alcoholic hepatitis have low short-term mortality rates (&lt;10 percent at one to three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H325299748\">",
"     'Determining disease severity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a pooled analysis of 661 patients with alcoholic hepatitis who had received placebo in randomized trials, the overall mortality rate after a median of 160 days was 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/4\">",
"     4",
"    </a>",
"    ]. The primary causes of death were hepatic failure (55 percent), gastrointestinal bleeding (21 percent), and sepsis (7 percent). When mortality rates were examined based on study inclusion criteria, one-month mortality rates were higher in trials that included only patients with severe alcoholic hepatitis compared with trials that included patients with both moderate and severe alcoholic hepatitis or trials that did not specify severity (23 versus 21 and 11 percent, respectively).",
"   </p>",
"   <p>",
"    A high mortality rate for patients with severe alcoholic hepatitis was also seen in a meta-analysis of five randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/6\">",
"     6",
"    </a>",
"    ]. Among 197 patients with severe alcoholic hepatitis who did not receive corticosteroids, the mortality rate at 28 days was 34 percent.",
"   </p>",
"   <p>",
"    Mortality rates for patients with mild to moderate alcoholic hepatitis have been reported in small trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of nutritional support, 12 patients had moderate alcoholic hepatitis. There were no deaths at 28 days among the patients with moderate alcoholic hepatitis, regardless of the treatment arm (whereas the mortality rate was 32 percent among those with severe alcoholic hepatitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial that included 26 patients with mild to moderate alcoholic hepatitis who did not receive treatment, 2 patients (8 percent) died [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple factors have been associated with increased mortality in patients with alcoholic hepatitis, some of which have been incorporated into prognostic models. (See",
"    <a class=\"local\" href=\"#H325299748\">",
"     'Determining disease severity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Factors associated with increased mortality include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Acute kidney injury",
"     </li>",
"     <li>",
"      Elevated bilirubin level",
"     </li>",
"     <li>",
"      Elevated INR",
"     </li>",
"     <li>",
"      Leukocytosis",
"     </li>",
"     <li>",
"      Alcohol consumption &gt;120",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"     </li>",
"     <li>",
"      Presence of infection (sepsis, spontaneous bacterial peritonitis, pneumonia, urinary tract infection)",
"     </li>",
"     <li>",
"      Hepatic encephalopathy",
"     </li>",
"     <li>",
"      Upper gastrointestinal bleeding",
"     </li>",
"     <li>",
"      A bilirubin to gamma glutamyl transferase ratio &gt;1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, extremely high white blood cell counts (a leukemoid reaction) are seen and are associated with very high mortality rates. In a review of 10 cases of patients with alcoholic hepatitis and a leukemoid reaction, the white blood cell counts ranged from",
"    <span class=\"nowrap\">",
"     57,000/microL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     129,000/microL,",
"    </span>",
"    and only one patient survived [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325299748\">",
"    <span class=\"h1\">",
"     DETERMINING DISEASE SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several models have been proposed to determine the severity of a patient's alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/13\">",
"     13",
"    </a>",
"    ]. The Maddrey discriminant function and the Model for End-stage Liver Disease (MELD) score are the most commonly used to help identify patients who are more likely to benefit from pharmacologic therapy. Other validated scores include the Glasgow alcoholic hepatitis score, the ABIC score (which includes age, serum bilirubin, international normalized ratio, and serum creatinine), and the Lille score (which is used to determine if a patients is responding to treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/13,16,17\">",
"     13,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H234081695\">",
"     'Glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251272027\">",
"    <span class=\"h2\">",
"     Maddrey discriminant function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease severity and mortality risk in patients with alcoholic hepatitis may be estimated using the Maddrey discriminant function (DF, also known as the Maddrey score), which is calculated as follows (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    For bilirubin in conventional units",
"    <span class=\"nowrap\">",
"     (mg/dL):",
"    </span>",
"   </p>",
"   <p>",
"    DF = (4.6 x [prothrombin time (sec) - control prothrombin time (sec)]) + (serum bilirubin)",
"   </p>",
"   <p>",
"    For bilirubin in syst&egrave;me international (SI) units",
"    <span class=\"nowrap\">",
"     (micromol/L):",
"    </span>",
"   </p>",
"   <p>",
"    DF = (4.6 x [prothrombin time (sec) - control prothrombin time (sec)]) + (serum",
"    <span class=\"nowrap\">",
"     bilirubin/17.1)",
"    </span>",
"   </p>",
"   <p>",
"    Patients with a DF value &ge;32 have high short-term mortality and may benefit from treatment with glucocorticoids, whereas those with lower scores have low short-term mortality and do not appear to benefit from glucocorticoids. (See",
"    <a class=\"local\" href=\"#H234081660\">",
"     'Natural history'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H234081695\">",
"     'Glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251272037\">",
"    <span class=\"h2\">",
"     Meld score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Model for End-stage Liver Disease (MELD) score is a statistical model developed to predict survival in patients with cirrhosis that has also been used to predict mortality in patients hospitalized for alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The score ranges from 6 to 40 and is based on the serum bilirubin, creatinine, and INR (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 2",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report, a MELD score &gt;11 performed as well as the DF in predicting 30-day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/19\">",
"     19",
"    </a>",
"    ]. The sensitivity and specificity of MELD for predicting 30-day mortality were 86 and 81 percent, respectively, and for the DF were 86 and 48 percent, respectively. In a second study, a MELD score of &ge;21 had a sensitivity of 75 percent and a specificity of 75 percent for predicting 90-day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, an increase in the MELD score of &ge;2 points in the first week of hospitalization may independently predict in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251272046\">",
"    <span class=\"h2\">",
"     Glasgow alcoholic hepatitis score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Glasgow alcoholic hepatitis score (GAH) predicts mortality in alcoholic hepatitis and is based on a multivariable model that includes age, serum bilirubin, blood urea nitrogen, prothrombin time, and peripheral white blood cell count (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?42/9/43152?source=see_link\">",
"     calculator 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. An initial validation study with 195 patients with alcoholic hepatitis found that a GAH score &ge;9 had lower sensitivity but higher specificity for predicting 28-day mortality than a DF of &ge;32 (81 versus 96 percent and 61 versus 27 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/23\">",
"     23",
"    </a>",
"    ]. Similar results were seen when it was compared with the MELD score (using a MELD cutoff of 11).",
"   </p>",
"   <p>",
"    A subsequent validation study with 225 patients with a DF &ge;32 found that patients with a GAH score &ge;9 who received glucocorticoids had higher survival rates compared with those who did not receive glucocorticoids (78 versus 52 percent survival at 28 days and 59 versus 38 percent survival at 84 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/22\">",
"     22",
"    </a>",
"    ]. However, no survival benefit with glucocorticoids was seen among the patients with a GAH score &lt;9.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081667\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of alcoholic hepatitis includes treatment for alcohol withdrawal, providing hemodynamic and nutritional support, and in those with severe alcoholic hepatitis (discriminant function [DF] &ge;32 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"     calculator 1",
"    </a>",
"    )), treating with either a glucocorticoid or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    . Patients with alcoholic hepatitis usually need to be admitted to the hospital for management. Admission to an intensive care unit (ICU) should be considered in patients who are unstable or combative. In addition, patients who are inebriated or encephalopathic should have their airway protected. In patients not being managed in an ICU, hospitalization should be continued if there is evidence of infection, renal failure, severe coagulopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver failure, alcohol withdrawal, delirium tremens, or other serious complications. Once these have been excluded and the patient is hemodynamically stable (with or without ongoing steroid usage), discharge can be considered, provided that there is sufficient social support and patient insight to ensure good compliance with medications, abstinence from alcohol, and close medical follow-up. Consultation with a gastroenterologist or hepatologist is recommended to assist with management, especially for patients who fail to respond to pharmacologic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081674\">",
"    <span class=\"h2\">",
"     General management for all patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with alcoholic hepatitis require general supportive care, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol abstinence",
"     </li>",
"     <li>",
"      Prevention and treatment of alcohol withdrawal",
"     </li>",
"     <li>",
"      Fluid management",
"     </li>",
"     <li>",
"      Nutritional support",
"     </li>",
"     <li>",
"      Infection surveillance",
"     </li>",
"     <li>",
"      Prophylaxis against gastric mucosal bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251271990\">",
"    <span class=\"h3\">",
"     Alcohol abstinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with alcoholic hepatitis should abstain from alcohol. Pharmacologic therapy with agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    may aid with abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Since many have a long history of heavy alcohol use, they are at risk for alcohol withdrawal. Therefore, the prevention and treatment of alcohol withdrawal is an important part of a patient's management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link&amp;anchor=H24#H24\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link&amp;anchor=H22#H22\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\", section on 'Baclofen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251272000\">",
"    <span class=\"h3\">",
"     Hydration and nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other supportive measures include ensuring appropriate hydration and nutritional support. Poor oral intake prior to presentation may result in dehydration, so many patients require fluid resuscitation. However, overhydration should be avoided, particularly in patients with stigmata of chronic liver disease suggestive of cirrhosis, since it may increase the degree of ascites, lower the plasma sodium concentration, and occasionally precipitate gastrointestinal hemorrhage from varices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with severe alcoholic hepatitis are malnourished and require nutritional support. High rates of malnourishment among patients with severe alcoholic hepatitis were demonstrated in a Veterans Administration Cooperative Study that included 284 patients with alcoholic hepatitis who underwent a complete nutritional assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/28\">",
"     28",
"    </a>",
"    ]. The study found that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of tissue wasting and severe protein-calorie malnutrition (eg, hypoalbuminemia, edema) were evident in almost all patients",
"     </li>",
"     <li>",
"      Indices of malnutrition correlated closely with the clinical severity of liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nutritional support includes providing adequate calories and protein, as well as vitamin (eg, thiamine, folate, and pyridoxine) and mineral (eg, phosphate, magnesium) repletion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/29\">",
"     29",
"    </a>",
"    ]. Vitamin K is usually given to patients with a prolonged prothrombin time, even though this regimen is often ineffective because the coagulopathy is more a reflection of underlying liver failure than vitamin K deficiency. Correction of the coagulopathy with fresh frozen plasma is",
"    <strong>",
"     not",
"    </strong>",
"    recommended unless there is active hemorrhage or the need to perform an invasive procedure. In theory, the volume expansion from fresh frozen plasma administration might increase the risk of variceal hemorrhage in a patient with portal hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/8/17544?source=see_link&amp;anchor=H430163212#H430163212\">",
"     \"Nutritional status in alcohol dependence\", section on 'Supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of vitamin K\", section on 'Treatment of coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of nutritional therapy in alcoholic hepatitis has been evaluated in multiple clinical trials, although there have been few studies in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/7,30-33\">",
"     7,30-33",
"    </a>",
"    ]. The majority of studies have demonstrated improvement in liver function and histology with nutritional therapy, though they have not consistently found reductions in mortality. In addition, a pilot, open-label study suggested that combining nutritional therapy with glucocorticoids might allow for a reduced course of glucocorticoids, but further studies are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the evidence suggesting a possible benefit with nutritional therapy, we suggest nutritional support for patients with alcoholic hepatitis. In general, enteral feeding is preferred over intravenous nutrition. Although protein ingestion is a theoretical risk factor for the development of hepatic encephalopathy, protein feeding is well tolerated in patients with alcoholic hepatitis, and protein should NOT be routinely restricted in such patients. In patients who develop encephalopathy associated with protein feeding, use of branched-chain amino acids may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=see_link&amp;anchor=H74885353#H74885353\">",
"     \"Nutritional assessment in chronic liver disease\", section on 'Alcoholic steatohepatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251272009\">",
"    <span class=\"h3\">",
"     Infection surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with evidence of possible infection (eg, fever, worsening mental status, hemodynamic instability) should have blood and urine cultures obtained. In addition, sputum cultures should be obtained if the patient has a productive cough or is intubated, and cerebrospinal fluid should be examined and cultured in those patients with fever and neurologic signs or symptoms that suggest CNS infection rather than typical hepatic encephalopathy (eg, headache with fever, nuchal rigidity, or lateralizing neurologic deficits). In addition, if present, ascitic fluid should be obtained for culture, cell count with differential, total protein, and albumin level. For patients with typical symptoms of hepatic encephalopathy, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    should be considered first, with further evaluation (including head imaging) to exclude other diagnoses if the patient does not improve. Cultures are required because it is often impossible to distinguish between the fever of hepatitis and that of infection based solely on clinical criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link&amp;anchor=H428430251#H428430251\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251272018\">",
"    <span class=\"h3\">",
"     Acid suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest prophylaxis against gastric mucosal bleeding with a proton pump inhibitor, H2-blocker, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    , particularly if the patient is in an intensive care unit, is receiving glucocorticoids, or has occult blood detected in the stool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link&amp;anchor=H7#H7\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of occult gastrointestinal bleeding\", section on 'Testing for occult blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081681\">",
"    <span class=\"h2\">",
"     Patients with mild to moderate alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment in patients with mild to moderate alcoholic hepatitis is abstinence from alcohol. In addition, general supportive care (eg, nutritional support and hydration) should be provided, but pharmacologic treatment with glucocorticoids is not recommended as it does not appear to be beneficial in patients with mild to moderate alcoholic hepatitis (Maddrey discriminant function [DF] &lt;32) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    has only been studied in patients with severe alcoholic hepatitis and not in patients with mild to moderate alcoholic hepatitis. (See",
"    <a class=\"local\" href=\"#H234081674\">",
"     'General management for all patients'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H234081695\">",
"     'Glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081688\">",
"    <span class=\"h2\">",
"     Patients with severe alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to general supportive care, pharmacologic treatment is indicated for patients with severe alcoholic hepatitis (DF &ge;32 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"     calculator 1",
"    </a>",
"    )).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     Prednisolone",
"    </a>",
"    has traditionally been used, though some studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    is effective and it lacks the side effects seen with glucocorticoids. (See",
"    <a class=\"local\" href=\"#H234081674\">",
"     'General management for all patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend treating patients with severe alcoholic hepatitis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    40 mg per day, provided there are no contraindications to its use (eg, active infection). We prefer prednisolone to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    because of the larger body of research supporting its use. Pentoxifylline 400 mg three times per day is an alternative in patients who are at risk for sepsis, but there are no data to support this approach. Treatment is continued for 28 days, though we stop therapy in patients who fail to show signs of improvement after a week of therapy (ie, those who fail to have improvement in their bilirubin or DF). For those who receive 28 days of prednisolone, we finish therapy with a 16-day prednisolone taper (we decrease the dose by 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every four days until a dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is reached, at which point we decrease it by 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every three days).",
"   </p>",
"   <p>",
"    The Lille score is one method to determine if patients with alcoholic hepatitis are responding to glucocorticoid therapy. The score was derived using a cohort of 295 patients with alcoholic hepatitis who were treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/16\">",
"     16",
"    </a>",
"    ]. It combines six variables: age, renal insufficiency (Cr &gt;1.3 or creatinine clearance &lt;40",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    albumin, prothrombin time, bilirubin, and evolution of bilirubin at day seven (bilirubin at day 7 &ndash; bilirubin at day 0). Online",
"    <a class=\"external\" href=\"file://www.lillemodel.com/score.asp?score=lillept\">",
"     calculators",
"    </a>",
"    are available for the calculating the Lille score.",
"   </p>",
"   <p>",
"    A score &gt;0.45 suggests that a patient is not responding to glucocorticoid therapy. In a validation cohort of 118 patients, 40 percent of patients had a Lille score &gt;0.45. Mortality at six months was higher among patients with a score &gt;0.45 compared with those who had a lower score (75 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, the Lille score performed better than the DF, Child-Pugh score, or GAH score in predicting survival at six months. Similarly, glucocorticoid treatment was not beneficial for patients with a high Lille score in a study that used a cutoff of &ge;0.56 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/6\">",
"     6",
"    </a>",
"    ]. We do not use the Lille score when deciding whether to continue treatment, but since it incorporates a bilirubin decrease in response to steroids, it may also be used. (See",
"    <a class=\"local\" href=\"#H234081695\">",
"     'Glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who fail to respond to medical therapy may require liver transplantation, though many are not considered candidates due to recent alcohol abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link&amp;anchor=H4#H4\">",
"     \"Liver transplantation in alcoholic liver disease\", section on 'Alcohol abstinence and psychosocial factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081695\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy for severe alcoholic hepatitis typically consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    40 mg per day for 28 days, followed by a taper over two to four weeks. Prednisolone is preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    because the latter requires conversion to prednisolone (the active form) in the liver, a process that may be impaired in alcoholic hepatitis.",
"   </p>",
"   <p>",
"    The efficacy of glucocorticoids in alcoholic hepatitis has been evaluated in multiple randomized trials and meta-analyses, with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/5,6,35-49\">",
"     5,6,35-49",
"    </a>",
"    ]. Mortality rates after one to six months among patients treated with glucocorticoids in these trials ranged from 15 to 63 percent. Some of the variability may be related to differences in disease severity among the trials. The preponderance of evidence suggests that the benefit of glucocorticoids is most evident in patients who have severe alcoholic hepatitis (see",
"    <a class=\"local\" href=\"#H325299748\">",
"     'Determining disease severity'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis that included 15 randomized trials with 721 patients, 40 percent of the patients died [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/46\">",
"       46",
"      </a>",
"      ]. While glucocorticoids did not reduce mortality overall, when the analysis was restricted to trials with patients with severe alcoholic hepatitis (DF &ge;32 or hepatic encephalopathy), there was a reduction in mortality (relative risk [RR] 0.37, 95% CI 0.16-0.86).",
"     </li>",
"     <li>",
"      Similarly, a meta-analysis that examined patient-level data from five randomized trials with 221 patients found that patients with severe alcoholic hepatitis treated with glucocorticoids had lower 28-day mortality rates than those treated with placebo (20 versus 34 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The survival benefit was only statistically significant in those with a Lille score &lt;0.56. The Lille score assesses improvement after one week of treatment, with lower scores indicating more improvement. Among patients with a Lille score &le;0.16, those who received glucocorticoids were less likely to die than those who received placebo (hazard ratio [HR] 0.18, 95% CI 0.05-0.71). A survival benefit with glucocorticoid treatment was also seen among patients with a Lille score &gt;0.16 and &lt;0.56 (HR 0.38, 95% CI 0.17-0.87). However, among patients with a Lille score &ge;0.56, the survival benefit with glucocorticoid treatment was not statistically significant (HR 0.81, 95% CI 0.45-1.45), though if true, a 19 percent reduction in mortality would be clinically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who fail to respond to glucocorticoid therapy, substituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    does not appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful monitoring for evidence of infection, gastrointestinal bleeding, or glucose intolerance is essential while the patient is on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    therapy. In one report, infection developed in 24 percent of 57 patients who received glucocorticoids and was more likely to develop in those who did not respond to glucocorticoids (43 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids have not been evaluated in patients with concomitant pancreatitis, gastrointestinal bleeding, renal failure, or active infection, as these conditions were exclusion criteria in many of the clinical trials. Our approach is to use glucocorticoids only in patients who qualify based on published criteria, and we do not treat with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    given the lack of efficacy data. However, other groups, including the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, do recommend pentoxifylline in patients who cannot receive glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/3,13\">",
"     3,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081702\">",
"    <span class=\"h3\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    inhibits tumor necrosis factor (TNF) synthesis, which is increased in patients with alcoholic hepatitis. Pentoxifylline (400 mg three times daily for 28 days) has been considered as an alternative to glucocorticoids in patients with severe alcoholic hepatitis (DF &ge;32), yet the data supporting its use are weak. Pentoxifylline may prevent hepatorenal syndrome, but a meta-analysis as well as preliminary results from a subsequent randomized trial suggest that it may not improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The meta-analysis included five trials with 336 patients. The initial analysis found that pentoxifylline was associated with reduced mortality compared with placebo (RR 0.64, 95% IC 0.46-0.89), but the benefit was not statistically significant after adjustment for multiple testing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, some of the individual trials were considered to be at risk for bias that may have overestimated the treatment effect. The meta-analysis did find a lower risk of death from hepatorenal syndrome with pentoxifylline, but with similar methodological concerns. Finally, one of the studies included in the analysis found an increased risk of serious and non-serious adverse events with pentoxifylline.",
"   </p>",
"   <p>",
"    A subsequent randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    for patients with severe alcoholic hepatitis has been reported in preliminary form. The trial included 270 patients with a DF &ge;32 who were assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    plus pentoxifylline or prednisolone plus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/52\">",
"     52",
"    </a>",
"    ]. There was no difference in mortality at six months between those who received pentoxifylline and those who did not (32 versus 31 percent, respectively). In addition, there was no difference in the rate of hepatorenal syndrome (9 versus 10 percent, respectively). Similarly, a trial with 70 patients failed to show a difference in six-month survival between patients treated with prednisolone plus pentoxifylline and those treated with prednisolone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite low quality evidence supporting its use,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    is commonly used for the treatment of patients with severe alcoholic hepatitis. This is likely due in part to its good safety profile and the lack of alternatives to glucocorticoids. In one study investigating clinician preferences for the treatment of severe alcoholic hepatitis, 29 percent of patients were treated with pentoxifylline, 25 percent were treated with glucocorticoids, and 6 percent were treated with both [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large randomized trial (STOPAH) is being conducted in the United Kingdom comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    with corticosteroids or a combination of both in patients with severe alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164407366\">",
"    <span class=\"h3\">",
"     Possibly effective treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other medical therapies have been investigated for the treatment of severe alcoholic hepatitis, though whether they will have a role in the routine treatment of alcoholic hepatitis is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Enteral nutrition",
"      </strong>",
"      &ndash; In addition to its role in the general management of patients with alcoholic hepatitis, nutritional therapy may have a role as an alternative to glucocorticoids in patients with severe alcoholic hepatitis, though additional trials are needed. A randomized trial with 71 patients with severe alcoholic hepatitis assigned patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or enteral tube feeding for 28 days and then followed the patients for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/58\">",
"       58",
"      </a>",
"      ]. Early mortality during treatment was similar in patients who received prednisolone and those who received enteral tube feeding (25 versus 31 percent, respectively), although deaths occurred later in those who received prednisolone (median 23 versus 7 days). Among the 51 patients who were discharged from the hospital, mortality over the long-term was higher in the prednisolone group (37 versus 8 percent).",
"     </li>",
"     <li>",
"      <strong>",
"       N-acetylcysteine &ndash;",
"      </strong>",
"      The combination of N-acetylcysteine (NAC), an antioxidant, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      has been studied for the treatment of severe alcoholic hepatitis, but it may not be more effective than prednisolone alone. A randomized trial with 174 patients compared treatment with either four weeks of prednisolone or four weeks of prednisolone plus NAC given on days one through five [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/59\">",
"       59",
"      </a>",
"      ]. There was no difference in six-month mortality (the primary endpoint) between those who received prednisolone and those who received prednisolone plus NAC (38 versus 27 percent, p = 0.07). While mortality was higher among those treated with prednisolone alone at one month (24 versus 8 percent, p&lt;0.01), the difference was no longer statistically significant at three months (34 versus 22 percent, p = 0.06). However, given the trend toward increased survival in those treated with NAC, additional study is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081709\">",
"    <span class=\"h3\">",
"     Ineffective treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ineffective treatments for alcoholic hepatitis that have been studied include anti-tumor necrosis factor (TNF) antibodies, anabolic steroids, and hepatic regeneration therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anti-TNF antibodies &ndash;",
"      </strong>",
"      TNF-alpha is believed to play a role in the pathogenesis of acholic hepatitis, but trials using anti-TNF antibodies have had disappointing results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis of alcoholic liver disease\", section on 'Injurious cytokines'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      is a soluble TNF receptor:FC fusion protein that binds to and neutralizes soluble TNF. While initial observational studies of etanercept showed a possible benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/60\">",
"       60",
"      </a>",
"      ], a randomized controlled trial in patients with moderate to severe alcoholic hepatitis did not [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/61\">",
"       61",
"      </a>",
"      ]. Compared with placebo, etanercept was associated with significantly higher mortality (mainly due to infection) after six months (58 versus 23 percent).",
"      <br/>",
"      <br/>",
"      Another anti-TNF antibody,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , has also been studied for the treatment of severe alcoholic hepatitis. Infliximab is a chimeric mouse-human anti-TNF monoclonal antibody that was associated with clinical improvement in open-label trials [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. Infliximab was then studied in a randomized trial with 36 patients with severe alcoholic hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/64\">",
"       64",
"      </a>",
"      ]. The patients were assigned to infliximab (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      at days 0, 14, and 28) or placebo. All patients also received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (40 mg daily) for 28 days. The study was stopped early due higher mortality at two months in the infliximab group (39 versus 18 percent), though the increase was not statistically significant. Infections were more common in the infliximab group (72 versus 17 percent, p = 0.002), with severe infections accounting for half of the deaths. The study was criticized because high doses of infliximab were used (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      at days 0, 14, and 28), though the open-label studies that used lower doses also found high infection rates [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. In addition, it is not known if the increased infection rate in the infliximab group was due to the infliximab alone or due to the combined effects of infliximab plus prednisolone.",
"     </li>",
"     <li>",
"      <strong>",
"       Anabolic steroids &ndash;",
"      </strong>",
"      Androgens have been used in an attempt to improve nutritional status in patients with alcoholic hepatitis, but they are likely ineffective. Promising results were seen in a subset of patents from a multicenter Veterans Administration trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"       oxandrolone",
"      </a>",
"      that included 263 patients with moderate or severe alcoholic hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/38\">",
"       38",
"      </a>",
"      ]. While there was no benefit in short-term survival, there was some benefit in long-term survival among patients who survived for at least one month. However, no benefit could be demonstrated in a systematic review of five randomized trials of patients with alcoholic hepatitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatic regeneration therapy &ndash;",
"      </strong>",
"      Several growth factors have been identified that influence hepatocyte regeneration, though their role in the treatment of patients with alcoholic hepatitis has yet to be established. The best studied in humans are insulin and glucagon, which have been evaluated in several randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/66-69\">",
"       66-69",
"      </a>",
"      ]. A treatment benefit has not been consistently demonstrated, and complications (including hypoglycemic deaths) have occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081716\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe alcoholic hepatitis who fail to respond to treatment with glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    may require liver transplantation. However, because alcoholic hepatitis implies recent alcohol abuse, such patients rarely receive transplantations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link&amp;anchor=H3#H3\">",
"     \"Liver transplantation in alcoholic liver disease\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164407509\">",
"    <span class=\"h2\">",
"     Patients with hepatorenal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe alcoholic hepatitis often develop renal failure, which is associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/9,70\">",
"     9,70",
"    </a>",
"    ]. Hepatorenal syndrome should be considered in patients with a rising creatinine despite fluid resuscitation and discontinuation of diuretics. The approach to the diagnosis and treatment of hepatorenal syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234081730\">",
"    <span class=\"h2\">",
"     Course after recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who recover from alcoholic hepatitis remain at risk for progressive liver disease, even if they abstain from alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In one series of 61 patients, 18 percent of those who initially had alcoholic hepatitis without cirrhosis progressed to cirrhosis despite alcohol abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/43/698/abstract/71\">",
"     71",
"    </a>",
"    ]. In addition, histologic features of alcoholic hepatitis persisted for up to 14 months after discontinuing alcohol, suggesting that resolution of inflammation is slow. Thus, even patients who abstain from alcohol require ongoing evaluation for the development of cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been our observation that a marked elevation in serum bilirubin with slow normalization of aminotransferases that remain in an alcoholic pattern (aspartate aminotransferase &gt; alanine aminotransferase) may be seen for many months following an episode of alcoholic hepatitis, even in patients who abstain from alcohol, perhaps reflecting the persistent histologic changes. Thus, the presence of persistently abnormal serum aminotransferases does not necessarily indicate that a patient is continuing to drink alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234083008\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with severe alcoholic hepatitis, short-term mortality rates are high (approximately 25 to 35 percent at one month), whereas patients with mild to moderate alcoholic hepatitis have low short-term mortality rates (&lt;10 percent at one to three months). (See",
"      <a class=\"local\" href=\"#H234081660\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several prognostic models have been proposed to determine the severity of a patient's alcoholic hepatitis. The Maddrey discriminant function (DF) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and Model for End-stage Liver Disease (MELD) are the most commonly used to identify patients with severe alcoholic hepatitis (DF &ge;32) who are more likely to benefit from pharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H325299748\">",
"       'Determining disease severity'",
"      </a>",
"      above.) The Lille score has also been well validated.",
"     </li>",
"     <li>",
"      Patients with alcoholic hepatitis require general supportive care, including (see",
"      <a class=\"local\" href=\"#H234081674\">",
"       'General management for all patients'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alcohol abstinence",
"     </li>",
"     <li>",
"      Prevention and treatment of alcohol withdrawal",
"     </li>",
"     <li>",
"      Fluid management",
"     </li>",
"     <li>",
"      Nutritional support",
"     </li>",
"     <li>",
"      Infection surveillance",
"     </li>",
"     <li>",
"      Prophylaxis against gastric mucosal bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mild to moderate alcoholic hepatitis (DF &lt;32), we recommend",
"      <strong>",
"       against",
"      </strong>",
"      pharmacologic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Prednisolone does not appear to be beneficial in such patients. In addition, we suggest",
"      <strong>",
"       against",
"      </strong>",
"      pharmacologic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Pentoxifylline has not been studied in this population, and its efficacy in patients with more severe alcoholic hepatitis is not clear. The mainstay of treatment for patients with mild to moderate alcoholic hepatitis is abstinence from alcohol and supportive care. (See",
"      <a class=\"local\" href=\"#H234081681\">",
"       'Patients with mild to moderate alcoholic hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe alcoholic hepatitis (DF &ge;32), we recommend pharmacologic therapy plus supportive care rather than supportive care alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H234081688\">",
"       'Patients with severe alcoholic hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients receiving pharmacologic therapy, we recommend treating with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      , provided there are no contraindications to glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We prefer prednisolone (40 mg per day for 28 days) to pentoxifylline because of the larger body of research supporting its use. After the 28-day course of therapy is complete, we taper the prednisolone over 16 days. (See",
"      <a class=\"local\" href=\"#H234081688\">",
"       'Patients with severe alcoholic hepatitis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If there are contraindications to the use of glucocorticoids, pentoxifylline can be considered, but the evidence of efficacy is weak, and it is not clear if it improves survival. Pentoxifylline is given as 400 mg three times per day for 28 days. (See",
"      <a class=\"local\" href=\"#H234081702\">",
"       'Pentoxifylline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      , we suggest stopping the medication if there is no sign of improvement (ie, decreasing bilirubin or DF) after a week of therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Since the Lille score incorporates a bilirubin decrease in response to steroids, it may also be used to determine if steroids should be continued. (See",
"      <a class=\"local\" href=\"#H234081688\">",
"       'Patients with severe alcoholic hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who fail to respond to medical therapy may require liver transplantation before a six-month waiting period. However, such patients must be very carefully selected to ensure a minimal risk of recidivism after transplant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link&amp;anchor=H4#H4\">",
"       \"Liver transplantation in alcoholic liver disease\", section on 'Alcohol abstinence and psychosocial factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/1\">",
"      Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/2\">",
"      Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/3\">",
"      O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. Hepatology 2010; 51:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/4\">",
"      Yu CH, Xu CF, Ye H, et al. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol 2010; 16:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/5\">",
"      Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/6\">",
"      Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/7\">",
"      Simon D, Galambos JT. A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis. J Hepatol 1988; 7:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/8\">",
"      Mezey E, Potter JJ, Rennie-Tankersley L, et al. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/9\">",
"      Altamirano J, Fagundes C, Dominguez M, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2012; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/10\">",
"      Altamirano J, Higuera-de laTijera F, Duarte-Rojo A, et al. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. Am J Gastroenterol 2011; 106:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/11\">",
"      Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011; 45:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/12\">",
"      Ali S, Hussain S, Hair M, Shah AA. Comparison of Maddrey Discriminant Function, Child-Pugh Score and Glasgow Alcoholic Hepatitis Score in predicting 28-day mortality on admission in patients with acute hepatitis. Ir J Med Sci 2013; 182:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/13\">",
"      European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/14\">",
"      Poynard T, Zourabichvili O, Hilpert G, et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984; 4:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/15\">",
"      Mitchell RG, Michael M 3rd, Sandidge D. High mortality among patients with the leukemoid reaction and alcoholic hepatitis. South Med J 1991; 84:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/16\">",
"      Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/17\">",
"      Dominguez M, Rinc&oacute;n D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/18\">",
"      Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/19\">",
"      Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/20\">",
"      Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/21\">",
"      Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/22\">",
"      Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/23\">",
"      Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/24\">",
"      Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/25\">",
"      Enserink M. Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy. Science 2011; 332:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/26\">",
"      Avanesyan A, Runyon BA. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcoholic hepatitis in a real-life clinical setting. Hepatology 2010; 52:1104A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/27\">",
"      Heydtmann M, MacDonald B, Lewsey J, et al. The GABA-B agonist baclofen imporves alcohol consumption, psychometrics and may have an effect on hospital admission rates in patients ith alcoholic liver disease. Hepatology 2012; 56:1091A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/28\">",
"      Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/29\">",
"      Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/30\">",
"      Bonkovsky HL, Fiellin DA, Smith GS, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991; 86:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/31\">",
"      Mezey E, Caballer&iacute;a J, Mitchell MC, et al. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991; 14:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/32\">",
"      Achord JL. A prospective randomized clinical trial of peripheral amino acid-glucose supplementation in acute alcoholic hepatitis. Am J Gastroenterol 1987; 82:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/33\">",
"      Diehl AM, Boitnott JK, Herlong HF, et al. Effect of parenteral amino acid supplementation in alcoholic hepatitis. Hepatology 1985; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/34\">",
"      Alvarez MA, Cabr&eacute; E, Lorenzo-Z&uacute;&ntilde;iga V, et al. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004; 16:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/35\">",
"      Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/36\">",
"      Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/37\">",
"      Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/38\">",
"      Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/39\">",
"      Depew W, Boyer T, Omata M, et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/40\">",
"      Shumaker JB, Resnick RH, Galambos JT, et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/41\">",
"      Blitzer BL, Mutchnick MG, Joshi PH, et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/42\">",
"      Campra JL, Hamlin EM Jr, Kirshbaum RJ, et al. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973; 79:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/43\">",
"      Porter HP, Simon FR, Pope CE, et al. Corticosteroid therapy in severe alcoholic hepatitis. N Engl J Med 1971; 284:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/44\">",
"      Mathurin P, Louvet A, Dharancy S. Treatment of severe forms of alcoholic hepatitis: where are we going? J Gastroenterol Hepatol 2008; 23 Suppl 1:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/45\">",
"      Reynolds TB, Benhamou JP, Blake J, et al. Treatment of acute alcoholic hepatitis. Gastroenterol Int 1989; 2:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/46\">",
"      Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/47\">",
"      Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/48\">",
"      Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/49\">",
"      Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/50\">",
"      Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/51\">",
"      Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/52\">",
"      Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: Results of the CORPENTOX trial. Hepatology 2011; 54:390A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/53\">",
"      Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; :CD007339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/54\">",
"      Sidhu SS, Goyal O, Singla P, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/55\">",
"      O'Shea R, Kinnard MF, Umar N, et al. Treatment of alcoholic hepatitis (AH) in clinical practice. Gastroenterology 2009; 136:A830.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.controlled-trials.com/ISRCTN88782125 (Accessed on January 29, 2013).",
"    </li>",
"    <li>",
"     www.stopah.com (Accessed on January 29, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/58\">",
"      Cabr&eacute; E, Rodr&iacute;guez-Iglesias P, Caballer&iacute;a J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/59\">",
"      Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/60\">",
"      Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/61\">",
"      Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/62\">",
"      Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/63\">",
"      Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009; 50:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/64\">",
"      Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/65\">",
"      Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2006; :CD003045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/66\">",
"      Baker AL, Jaspan JB, Haines NW, et al. A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology 1981; 80:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/67\">",
"      Feh&eacute;r J, Cornides A, Rom&aacute;ny A, et al. A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis. J Hepatol 1987; 5:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/68\">",
"      Bird G, Lau JY, Koskinas J, et al. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991; 14:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/69\">",
"      Trinchet JC, Balkau B, Poupon RE, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992; 15:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/70\">",
"      Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/71\">",
"      Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 1972; 63:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/43/698/abstract/72\">",
"      Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol 1987; 4:364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87052 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_698=[""].join("\n");
var outline_f0_43_698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H234083008\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234083145\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234081660\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H325299748\">",
"      DETERMINING DISEASE SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251272027\">",
"      Maddrey discriminant function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251272037\">",
"      Meld score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251272046\">",
"      Glasgow alcoholic hepatitis score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234081667\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234081674\">",
"      General management for all patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H251271990\">",
"      - Alcohol abstinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H251272000\">",
"      - Hydration and nutritional support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H251272009\">",
"      - Infection surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H251272018\">",
"      - Acid suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234081681\">",
"      Patients with mild to moderate alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234081688\">",
"      Patients with severe alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234081695\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234081702\">",
"      - Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H164407366\">",
"      - Possibly effective treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234081709\">",
"      - Ineffective treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234081716\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164407509\">",
"      Patients with hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234081730\">",
"      Course after recovery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234083008\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/87052\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/87052|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/61/5079\" title=\"figure 1\">",
"      Definition standard drink",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=related_link\" title=\"calculator 1\">",
"      Calculator: Hepatitis discriminant function for corticosteroid therapy in alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=related_link\" title=\"calculator 3\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?42/9/43152?source=related_link\" title=\"calculator 4\">",
"      Calculator: Glasgow alcoholic hepatitis score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=related_link\">",
"      Liver transplantation in alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=related_link\">",
"      Nutritional assessment in chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/8/17544?source=related_link\">",
"      Nutritional status in alcohol dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_43_699="Suspicion for vestbulodynia";
var content_f0_43_699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient comments that should raise suspicion of vestibulodynia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        I can't use tampons because they hurt.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You need to use your smallest speculum when you examine me.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My last doctor told me to relax more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I always have a yeast infection, but therapy doesn't help.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My episiotomy stitches still hurt.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I'm too tight down there.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex has been painful since menopause.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_699=[""].join("\n");
var outline_f0_43_699=null;
var title_f0_43_700="Sample heat acclimatization program for American football";
var content_f0_43_700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample heat acclimatization program for American footbball",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Modification",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Practices 1-5",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Practices 6-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Days 1-2",
"       </td>",
"       <td class=\"subtitle2\">",
"        Days 3-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of practices permitted per day",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2 (only every other day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equipment",
"       </td>",
"       <td>",
"        Helmets only",
"       </td>",
"       <td>",
"        Helmets &amp; shoulder pads",
"       </td>",
"       <td>",
"        Full equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximum duration of practice session",
"       </td>",
"       <td>",
"        3 hours",
"       </td>",
"       <td>",
"        3 hours",
"       </td>",
"       <td>",
"        3 hours (maximum of 5 hours total on double session days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permitted walk through time (in addition to regular practice session)",
"       </td>",
"       <td colspan=\"2\">",
"        1 hour (must be separated from regular practice by 3 hours)",
"       </td>",
"       <td>",
"        1 hour (must be separated from regular practice by 3 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contact",
"       </td>",
"       <td>",
"        No contact",
"       </td>",
"       <td>",
"        Contact only with blocking sleds/dummies",
"       </td>",
"       <td>",
"        Full contact drills",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Warm-up, stretching, cool-down, conditioning, and weight-room activities are all included as part of practice time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Preseason Heat-Acclimatization Guidelines for Secondary School Athletics.&nbsp;Journal of Athletic Training 2009; 44:332.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_700=[""].join("\n");
var outline_f0_43_700=null;
var title_f0_43_701="Comparison of pneumococcal conjugate and polysaccharide vaccines";
var content_f0_43_701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of pneumococcal conjugate and pneumococcal polysaccharide vaccines used in children in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        13-valent pneumococcal conjugate vaccine",
"        <br/>",
"        (PCV13)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pneumococcal polysaccharide vaccine",
"        <br/>",
"        (PPSV23)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Trade name",
"        </strong>",
"       </td>",
"       <td>",
"        Prevnar 13&trade;",
"       </td>",
"       <td>",
"        Pneumovax",
"        <sup>",
"         &reg;",
"        </sup>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Serotypes contained",
"        </strong>",
"       </td>",
"       <td>",
"        1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F",
"       </td>",
"       <td>",
"        1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Protein carrier",
"        </strong>",
"       </td>",
"       <td>",
"        CRM197 (a nontoxic mutant of diphtheria toxin)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Adjuvant",
"        </strong>",
"       </td>",
"       <td>",
"        Aluminum phosphate",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Contains thimerosal?",
"        </strong>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        May contain thimerosal as a preservative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dose",
"        </strong>",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Route",
"        </strong>",
"       </td>",
"       <td>",
"        Intramuscular",
"       </td>",
"       <td>",
"        Intramuscular or subcutaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Target groups",
"        </strong>",
"       </td>",
"       <td>",
"        All infants and children younger than five years",
"       </td>",
"       <td>",
"        Individuals &ge;2 years at increased risk for pneumococcal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Approved age groups",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         6 weeks through 17 years;",
"        </p>",
"        &ge;50 years",
"       </td>",
"       <td>",
"        &ge;2 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Number of doses",
"        </strong>",
"       </td>",
"       <td>",
"        Varies depending on age when series is initiated",
"       </td>",
"       <td>",
"        One or two depending upon risk group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Recommended schedule",
"        </strong>",
"       </td>",
"       <td>",
"        2, 4, 6, and 12 to 15 months",
"       </td>",
"       <td>",
"        <p>",
"         One dose of PPSV23 at age &ge;2 years and &ge;8 weeks after the last indicated dose of PCV13.",
"        </p>",
"        <p>",
"         A second dose (five years after the first) is recommended for children who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia.",
"        </p>",
"        A second dose is",
"        <strong>",
"         not",
"        </strong>",
"        recommended for immunocompetent children with cochlear implants or chronic illness, including chronic heart disease, chronic lung disease, diabetes mellitus, and cerebrospinal fluid leaks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         May be administered with other vaccines?",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_701=[""].join("\n");
var outline_f0_43_701=null;
var title_f0_43_702="AR postoperative outcome";
var content_f0_43_702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Long-term postoperative survival in aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with aortic regurgitation who are in functional class I or II before surgery have a survival after surgery that is similar to that expected in an age and gender matched normal population. In contrast, the outcome among patients who are in functional class III or IV before surgery is worse than for those with functional class I and II (p",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Klodas, E, Enriquez-Sarano, M, Tajik, AJ, et al, J Am Coll Cardiol 1997; 30:746.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_702=[""].join("\n");
var outline_f0_43_702=null;
var title_f0_43_703="Hydrocarbon ingestion management";
var content_f0_43_703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disposition after hydrocarbon ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 563px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NPO: nothing by mouth; IV: intravenous; CXR: chest radiograph.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_43_703=[""].join("\n");
var outline_f0_43_703=null;
